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Abstract

SYNTHESIS AND BIOLOGICAL EVALUATION OF ANIBAMINE AND ITS ANALOGS AS
NOVEL ANTI-PROSTATE CANCER AGENTS
By Kendra May Haney

A Thesis submitted in partial fulfillment of the requirements for the degree of Master of Science at
Virginia Commonwealth University

Virginia Commonwealth University, 2009

Major Director: Yan Zhang, Assistant Professor, Department of Medicinal Chemistry

The chemokine receptor CCR5 has been implicated in the pathogenesis of prostate
cancer. A novel natural product, anibamine, was isolated and found to be a micromolar inhibitor
of the receptor. Anibamine was used as a new anti-prostate cancer lead compound. To discover
the pharmacophore, analogs of anibamine were designed using the “deconstructionreconstruction-elaboration” approach and synthesized. The establishment of a stereoselective
route to only one isomer was explored, to increase yield and eliminate elaborate purification
procedures. Analogs were found to have anti-prostate cancer activity at levels higher than the
parent compound. The molecular modeling studies of the deconstructed analogs indicate that due

xvii

to the psuedo-symmetry of the parent compound, the binding conformation of the deconstructed
analogs may not be very different from each other. All this information together may help
identify a next generation lead compound for anti-prostate cancer treatment.

1

I. Introduction

Prostate cancer (PCa) is the most common cancer in men after lung cancer.1 The
American Cancer Society estimates that nearly 200,000 new cases of PCa will be diagnosed in
2009, with 27,000 deaths attributable to PCa in the United States alone.2 Better detection rates
have helped those in the early stages of cancer but there is no cure for the metastatic disease. Age
is the greatest risk factor3 and with an ever increasing population of men over the age of 50,
establishment of successful treatment of PCa proliferation, angiogenesis, and metastasis is in
high demand. Though the cause of prostate cancer is unknown, chronic inflammation (CI) has
been implicated as playing a role in the pathogenesis of PCa.4 Nearly one and half centuries ago,
Rudolf Virchow noticed that cancers often occurred at sites of chronic inflammation.5 Since then
several cancers have been attributed to CI, including cancers of the liver, colorectum, ovary and
cervix.5
Suspicion of the influence of inflammation on PCa development led to the discovery that
the chemokine receptor, CCR5, is overexpressed in PCa tissues when compared to the noncancerous condition, benign prostate hyperplasia (BPH).6 Chemokine receptor CCR5 is part of
the chemokine network which plays an important role in the immune system by attracting
leukocytes to sites of inflammation. CCR5 and another chemokine receptor, CXCR4, were found
to be essential co-receptors for the invasion of the human immunodeficiency virus, HIV, into
cells.7 This discovery sparked an urgent search for CCR5 antagonists by high-throughput
screening of small molecule libraries. The existence of phenotypically normal people with a
mutated, inactive CCR5 gene that essentially renders them immune to human immunodeficiency
virus (HIV) infection lends some substance to the suitability of blocking this particular receptor.8
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To date only one of several CCR5 antagonist drug candidates has passed the FDA’s rigorous
screening process to become an approved drug as an HIV-1 entry inhibitor.9 Maraviroc is the
only chemokine receptor antagonist to gain approval for any therapeutic use. Another CCR5
antagonist, TAK-779, was found to inhibit the proliferation of PCa cell lines in vitro.10
Screening of a natural product extract led to the discovery that anibamine, a charged
alkaloid from the species Aniba panurensis, was a CCR5 antagonist at the micromolar level.11
Anibamine was also tested against the National Cancer Institute’s panel of 60 cancer cell lines.12
Anibamine was hemolytic and had a high logKo/w value making it initially unsuitable as drug
candidate. Preliminary studies have shown that anibamine also inhibits proliferation of prostate
cancer cell lines.13 In order to enhance the anti-cancer properties and reduce undesirable toxicity,
further refinement of the lead structure was necessary.
The total synthesis of anibamine was accomplished recently in our lab.14 Using
anibamine as a new lead compound, multiple analogs were designed following the
“deconstruction-reconstruction-elaboration” approach for discovering the pharmacophore and
ideally a next generation lead compound. The synthetic route accommodates the synthesis of
multiple analogs along diverted synthesis schemes. The purpose of this project was to synthesize
anibamine and deconstructed analogs. Following the synthesis a number of analogs were tested
for anti-proliferative effect in multiple metastatic prostate cancer cell lines. Binding modes of
synthesized ligands were also analyzed using computer generated models of CCR5 based on the
crystal structures of fellow G-protein coupled receptors (GPCR), bovine rhodopsin and human
beta-2 adrenergic receptor. All this information together may help identify a next generation lead
compound for anti-prostate cancer treatment.
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II. Background

A. Prostate cancer
Prostate cancer is one of the leading causes of cancer death for American men. The
primary cause of prostate cancer remains unclear, though chronic inflammation is believed to
play a role in its development. With increasing life expectancies as well as a surge in male
population over 50 years old, PCa is likely to become even more prevalent. Current therapies
have little effect on preventing or treating metastases though they may benefit early stages.15
Though PCa is generally a slow progressing adenocarcinoma, development of bone metastases is
ultimately fatal.16,17

1. The prostate and prostatic disorders
The prostate is a secretory gland in the male reproductive system surrounding the
prostatic urethra. The anatomy of the prostate is classified into four different zones; the
peripheral zone , the central zone, the transition zone , and the anterior fibromuscular zone. Most
prostate carcinomas arise from the peripheral zone and about one-third arise from the transitional
zone.18 The cells of the prostate are of three distinct cell types; secretory luminal, basal, and
endocrine-paracrine (EP) cells.19 Secretory luminal cells produce prostate specific antigen (PSA)
and express androgen receptor (AR). PSA is a glycoprotein that is used in early detection of
PCa.20 AR is a nuclear receptor that upon binding to the hormones testosterone or
dihydroxytestosterone (DHT) increases the transcription of genes involved in cell growth and
differentiation.15,21 Basal cells are androgen independent but a small amount are androgen
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responsive.19 The androgen responsive basal cells are believed to be the progenitor cells of the
secretory luminal cells and endocrine-paracrine cells.18 Maitland and Collins suggest that there is
a spectrum of differentiation between the basal cells and secretory luminal cells.19 The primary
function of the prostate is to secrete proteins necessary for sperm function. In normal prostate
tissue, growth and differentiation are regulated by circulating hormones and growth factors from
the surrounding stroma.19 The biggest surge in development of the prostate is during puberty.18
Later in life, the prostate can be the source of many complications.
There are several medical problems associated with the prostate. In the transitional zone,
benign prostatic hyperplasia (BPH) and atypical adenomatous hyperplasia (AAH) are common
maladies. Proliferative inflammatory atrophy (PIA) and prostate intraepithelial neoplasia (PIN)
are lesions commonly found in the peripheral zone. PCa occurs most commonly in both
transitional and peripheral zones. Studies and comparisons of several different prostatic tissues
can benefit the understanding the causes of PCa and how to prevent and treat PCa development
and metastasis.6,17
The maladies of the transitional zone are benign prostate hyperplasia and AAH. BPH is a
non-cancerous enlarged prostate, the symptoms of which are often confused with PCa. With
progressing age, the balance between androgens and estrogens acting on prostatic cells changes.
An age-related reduction in DHT circulation may be involved in development of BPH. The
number of androgen responsive basal cells proliferating increases in BPH compared to the
normal tissue which results in abnormal secretory luminal cell counts. This is considered a
differentiation issue rather than a regulatory abnormality19 which makes BPH non-cancerous.
Also there is a significant amount of inflammatory cells in the stroma surrounding BPH tissues.4
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In AAH, the proliferation compartment resembles normal and BPH tissue, meaning the basal
cells are the predominant type of cells proliferating.19 Proliferation rates for AAH range between
the relative rates of BPH and PCa.22 It has been suggested that AAH is an intermediary in
differentiation from BPH to transitional zone PCa22 as AAH resembles low grade PCa.19
Bonkhoff and Remberger state that neoplasms that might originate from AAH generally are not
be lethal.19 Comparing BPH, AAH and PCa can identify factors that lead to PCa in the
transitional zone.
Two common lesions appear in the peripheral zone that may lead to PCa. PIA, as
described by De Marzo et. al, is characterized by focal atrophy interspersed between normal
tissue and inflammatory cells. PIA lesions increase with age and are commonly found with areas
of PCa.4,23 Many instances of PIA are highly proliferative and have decreased apoptosis due to
irregularities in Bcl-2, an apoptosis regulating protein.4 Mutation of the p53 oncogene is also
seen in PIA.4 In PIN, the secretory luminal cells proliferate, when normally secretory luminal
cells do not proliferate.19 Like PCa, expression of Bcl-2 is increased, resulting in increased
lifespan of the secretory luminal cells. It has been hypothesized that PIA may either lead directly
to PCa or develop into PIN which may also develop into PCa.23
Comparison of the phenotypes of the different prostatic conditions have helped to unearth
mechanisms of prostate cancer development. The differentiation of the proliferating cells as well
as the rate of proliferation are the most distinguishable characteristics among the different
prostatic conditions. In the long term progression from normal prostatic epithelial cells to
prostate adenocarcinoma a number of mutations and alterations have been documented including
the common oncogene p53. Somatic changes in AR occur in most PCa tissues. Receptor
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overexpression coupled with signal amplification can make the remaining receptors very
sensitive to decreased hormone levels during androgen withdrawal therapy.15 Change in ligandspecificity has also been noted, allowing the AR receptors to be activated by other hormones as
well as AR activation through other growth factor networks.15 Initial success with androgen
ablation is usually curtailed by the development of androgen independent malignancies. After
this point, there is little hope for remission.

2. Prostate cancer cell lines
Standardized in vitro models of PCa can help pinpoint effects of different factors while
the use of immortalized normal prostatic epithelial cells can serve as controls for these
experiments. Human cell models can help address unknowns regarding regulation and
differentiation. Also using immortalized normal cells and malignant cells are useful in finding
methods to block angiogenesis, invasion, and metastasis.21
The PC-3 prostate cancer cell line was originally removed from the lumbar vertebra of a
62 year old caucasian man. It was described as “poorly differentiated prostatic adenocarcinoma.”
Hormone therapy was used to treat the patient.24 PC-3 is androgen independent, which could be
related to the use of hormone therapy to select for AR unresponsive malignant cells. PC-3 also
does not express PSA. Bone marrow transferrin stimulates growth of this cell line. PC-3
expresses high levels of the growth factors transforming growth factor-! (TGF-!) and insulinlike growth factor-1(IGF-1); fibroblast growth factor receptor (FGF-R), TGF-!-R, and IGF-1-R
are also seen in PC-3, possibly resulting in an autocrine growth loop.24
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DU-145 was derived from a central nervous system PCa metastasis. The patient was also
a Caucasian man in his 60s treated with androgen withdrawal therapy. Consequently, DU-145 is
also mostly androgen independent. High expression of endothelial growth factor (EGF), EGF-R,
IGF-1 and IGF-1-R and TGF-" are observed in this cell line, also resulting in possible autocrine
growth loops.24 DU-145 has mutations in the common oncogene p53.20
The M12 cell line is derived from the immortalized prostatic epithelial cell line,
P69SV40T.25,26 P69SV40T was injected into athymic mice subcutaneously and tumors formed in
two of eighteen mice after nine months. After selecting for invasiveness after successive
injections, the cell line M12 was found to invasive and have a shorter latency time of two weeks
when compared to the parent cell line. Subsequent intraperitoneal injections of the M12 cell line
into nude mice developed into metastases in the lungs and diaphragm consistently.25,26
Chromosomal investigations showed that the M12 subline lost 16q and gained 8q which are both
frequently observed chromosomal abnormalities in PCa tissue.26

3. Inflammation and Prostate Cancer
As previously mentioned, chronic inflammation has been accused of playing a role in the
development of prostate cancer. Both BPH and PIA are associated with inflammatory cells in
prostatic tissue. Of note is that prostatitis, inflammation of the prostate, is the most commonly
diagnosed prostatic condition.18 Chronic inflammation is a persistent inflammatory response,
lasting months to years. The immediate stimulus for an inflammatory response in prostatic tissue
is unknown. Men with a reported history of sexually transmitted infections, like gonorrhea and
syphilis, have increased risk of PCa.27 One virus, human papillomavirus (HPV) is known to
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cause cervical cancer. At least two viruses, human papovavirus BK and Xenotrophic MuLVrelated virus, have been detected in abnormal prostatic tissue.18 These infections may trigger an
inflammatory response in the prostatic tissue. There is also evidence that carcinogens reach the
prostatic tissue and may result in chemical damage that induces an immune response.18 The
influx of inflammatory cells can damage the prostatic tissue by production of reactive nitrogen
and oxygen species, thereby inducing increased proliferation of cells to replace those lost and
which can lead to development of somatic mutations.18 Another possible consequence of an
inflammatory response and cause of cancer is the selection of mutated progenitor cells that may
thrive in the inflammatory environment.18 After the immune response wanes, these selected cells
may undergo apoptosis, lay dormant until further stimulation or they might have developed an
autocrine growth pattern, leading to cancer.18 Because of the possible role inflammation plays in
prostate cancer development, several genes and proteins of the inflammatory network have been
studied in PCa and other prostatic tissues.
Chronic inflammation may lead to either BPH or PCa. Konig et al. studied the presence
of inflammatory proteins in both BPH and certain PCa cell lines, PC-3 and LnCAP. They found
that IL-8 and CCL5 were expressed more frequently in PCa than in BPH. CCR5 and MMP-9
also had higher expression in PCa. BPH had a higher expression of CCR3, CXCR-4, and cox-II
when compared to PCa.6

4. CCR5 and CCL5/RANTES in PCa
Konig et al. reported the increased expression of both CCR5 and RANTES (Regulated
upon Activation Normal T cell Expressed) in PCa compared to BPH. Further study into the role
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of these members of the chemokine/chemokine receptor family has been undertaken. Vaday et al.
reported that PCa cell lines, LNCaP, DU-145 and PC-3, express mRNA for RANTES to different
degrees. LNCaP and DU145 secrete higher levels of RANTES than PC-3.10 These cell lines also
express CCR5 mRNA and surface CCR5. This led the authors to the idea that this ligandreceptor pair has developed into an autocrine feedback loop to promote growth of PCa cells. The
authors also used RANTES and a CCR5 small molecule antagonist, TAK-779, to determine
whether RANTES can induce invasion in PCa cells as it has been shown to do in breast cancer
cell lines.10 The CCR5 antagonist inhibited both proliferation and invasion of PCa cell lines in
the presence of RANTES. The ligand-receptor pair RANTES/CCR5 may play a role in the
growth and invasiveness of PCa.
Polymorphisms in both RANTES and CCR5 are present in human populations. A few
studies have looked at allelic frequency of normal and abnormal RANTES and CCR5. SáenzLópez et al. found a statistically significant increase in Allele A vs Allele G in RANTES. Higher
transcription is reported with Allele A.28 An Italian group studied the CCR5#32 genetic mutation
in Sicilian patients with PCa compared to men over 100 years old without PCa. The CCR5#32
mutation results in a non-functioning receptor that is not expressed on the cell surface. Balistreri
et al. found that the centenarian population had more CCR5#32 mutations than the PCa
population, which suggest that in this European population, the CCR5 mutation may have a
protective effect in the development of PCa.29 However, another study in Australia indicated that
there was no difference in PCa risk between CCR5 or RANTES alleles.30 They did observe that
men with the CCR5#32 gene had a moderately higher incidence of PCa if there were two or
more immediate family members that also had PCa but it was unclear whether other family
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members were carriers of the same alleles.30 More study is needed in larger populations to
ascertain whether these genetic polymorphisms do indeed produce an increased susceptibility or
protective effect in development of PCa.

5. Prevention and Treatment
While the exact cause of PCa remains elusive, so does effective preventive measures. Use
of NSAIDs has been shown to decrease prostate cancer development4,18 but these studies have
been retrospective in nature, relying on the recollective abilities of the subjects. Age is still the
primary risk factor for developing PCa, followed by heredity and ethnicity.3 Dietary habits have
come under scrutiny as a possible risk factor, especially since geography appears to play more of
a role in defining susceptibility than ethnicity3 as in Asian migrants to areas of high incidence
also experience an increased incidence over a generation.31 After diagnosis of PCa, surgery,
radiation therapy or hormonal treatment with diethylstilbestrol or luteinizing hormone-releasing
hormone is intended to slow growth by stopping the growth factor function of AR. However this
may lead to selection of androgen unresponsive tumors.20 Some chemotherapeutic approaches
include 5-fluoruracil, taxol and cisplatin, but these can lead to drug resistance. The DU145 cell
line is particularly resistant to cisplatin.20 More treatments for the metastasis of PCa are needed
because of the morbidity associated with metastatic spread.

B. Chemokines and Chemokine Receptors
The chemokine/chemokine receptor system is a critical mediator of cell motility in
routine immune surveillance, inflammation, and development. The immune system depends on
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the chemokine system to guide needed lymphocytes to sites of tissue damage or antigen
presentation. Irregularities in these proteins can contribute to HIV infection, inflammatory
diseases and cancer. Due to this disease involvement, chemokines and their receptors have been
scrutinized as a means to both better understand and treat these conditions. The chemokine
receptor CCR5 has been shown to be an HIV invasion coreceptor and involved in proliferation of
neoplastic cells in various types of cancers, including prostate cancer.

1. Chemokine and Chemokine Receptor Structure and Signaling
Chemokines are so named because they are chemotactic cytokines. The class is composed
of nearly 50 soluble proteins ranging from 70 to 130 amino acids with the exception of CX3CL1
(fractalkine) and CXCL16 which are much larger and can be tethered to the cell surface by a
mucin-like stalk. The chemokines are split into 4 families, based on the relative positions of two
conserved cysteine residues that form disulfide bonds with other cysteines. In the CC chemokine
family, the cysteines are adjacent. In the CXC and CX3C chemokine families, the X represents
the number of non-cysteine residues that separate the conserved pair. In the C family of
chemokines, there exists only one N-terminus cysteine residue.32 Though chemokines share from
a low 20% to a high 90% homology among each other,33 the soluble chemokines retain a
characteristic fold with an unstructured N-terminus critical for binding to their receptors, a 3
stranded !-sheet connected by loops and turns with an " helical C-terminus.32 Chemokines
function to create a chemical gradient, helped by binding to glysoamino glycans (GAGs) on
epithelial cell surfaces, in order to attract various immune cells to sites of infection. Immune
cells express chemokine receptors on their cell surface and move toward the source of the
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gradient which can be various cells involved in the immune response. Chemokines bind to
chemokine receptors.
Chemokine receptors are also grouped into 4 families, according to which chemokine
they bind. Hence, CC receptors bind CC chemokines, etc. There are 20 known signaling
chemokine receptors and 3 “scavenger” receptors that do not induce a signaling cascade.33
Chemokines and their receptors exhibit a multitude of promiscuity, with many chemokines
binding different receptors and vice versa, though members of each family of ligands only bind
members of the same family of receptors. This redundancy may allow for fine tuning of immune
response; oligomerization of ligands and/or receptors, temporal and spatial
compartmentalizations also attenuate this complex system.33 Chemokine receptors are G-protein
coupled receptors (GPCRs) having 7 transmembrane helices, 3 extra-cellular loops, 3 intracellular loops, an extra-cellular N-terminus and an intracellular C-terminus with a molecular
weight around 350 kDa. Most chemokine receptors have a highly conserved DRYLA amino acid
sequence in the second intracellular loop.34 Chemokine receptors are mostly coupled to G"i
proteins and are inhibited by pertussis toxin, though there is evidence for coupling to other Gproteins.32,34 It has been suggested that receptor/G protein pairings may be cell type specific34 or
depend on the chemokine ligand.35 There is ample evidence for receptor hetero- and homodimerization, as well as higher order oligomers.36 Dimers can activate pathways distinct from
monomeric proteins.34 Any cell type can express chemokines or their receptors37 though
leukocytes including monocytes, dendritic cells, eosinophils, lymphocytes, and natural killer
cells but not neutrophils express CC chemokines and receptors.5 Receptor expression is
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determined by cell lineage and stage of differentiation but microenvironmental conditions like
growth factors, cytokines, hormones and hypoxia can modulate receptor expression.5,34

2. Chemokines and the Tumor Microenvironment
In 1863 Rudolf Virchow observed that cancers often occured at sites of chronic
inflammation, connecting luekocyte infiltration with neoplastic tissues.5 Nearly one and a half
centuries later, 15% of the cancers worldwide are related to infectious agents, involving chronic
inflammation.5 The influx of leukocytes into the area surrounding and in between tumor cells
has prompted the study of the tumor microenvironment as a whole, instead of focusing only on
cancer cells.19
Tumor associated chemokines play several roles in the tumor microenvironment,
including directing the infiltration of leukocytes to the tumor microenvironment, acting as
growth factors, encouraging angiogenesis, directing migration and evading the host immune
response. The tumor microenvironment and tissue at the peak of an inflammatory response
resemble one another.32In the tumor microenvironment, host luekocytes termed “tumor
infiltrating leukocytes” (TIL) are found in both the surrounding stroma and tumor areas.
Chemokines recruit and control the TIL.38 TIL may contribute to the growth, spread, and
immunosuppression of tumors. Chemokines can also act as growth factors, either through
autocrine or paracrine pathways. In many cancers that express the chemokine receptor, CXCR4,
there is evidence that the CXCR4 ligand, CXCL12, stimulates growth and proliferation of cancer
cells.38 In addition, other growth factor expression levels are associated with expression of
chemokine receptors on cancer cells.7 The other roles of chemokines in the tumor
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microenvironment, direction of migration and manipulating the host immune response, will be
discussed in more detail.

a) Chemokines and Immunotolerance
Although immune cells are present in the tumor microenvironment, their anti-tumorigenic
properties are inadequate. This phenomenon is not fully understood and there are two prevailing
(but not mutually exclusive) hypotheses to explain how the tumor cells escape immune
surveillance; the macrophage balance hypothesis and immune tolerance through commandeering
of the chemokine system.39 Tumor associated macrophages are capable, with appropriate
stimulation, to either kill the tumor cells or induce damage to the vascular endothelium.5 They
also have the capacity to encourage tumor cell proliferation and tumor ability to generate new
vasculature, migrate and metastasize through the production of growth and angiogenic factors.5
Secreted CCL2 recruits tumor associated macrophages to the tumor microenvironment.5
Chemokines, macrophages and disease outcome are related to each other but the relationship
varies between cancers and is termed the “macrophage balance hypothesis.”32,40
Another leukocyte component of the tumor microenvironment are tumor associated
dendritic cells (TADC). Dendritic cells are antigen presenting cells that provide a link between
adaptive and innate immunity by both participating in the triggering of antigen specific immunity
and the establishment of immunotolerance.5 Tumors secrete chemokine that are active on
immature dendritic cells (iDC) including CCL2, CCL7, CCL8 and the CCR5 ligands, CCL3,
CCL4 and CCL5 which can lead them to the tumor microenvironment.41 Generally the TADC
are immature in development and incapable of eliciting appropriate effector responses; immature
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dendritic cells can take up antigen but are dysfunctional in presenting antigen.7 Like TAM, tumor
associated dendritic cells also have the capability of being either pro-tumorigenic (through
angiogenic factors and tolerance inducing factors) or anti-tumorigenic (by T-cell activation).32 It
has been suggested that the quantity and quality of signals to immature dendritic cells determine
whether they will activate T-cell populations to fight cancer, remain inside the tumor
microenvironment and not elicit any immune response, or migrate to lymph nodes and induce
tolerance to the tumor.41 A key factor in immature dendritic cell maturation is expression of the
chemokine receptor CCR7 which can direct them to lymph nodes by lymphatic vessel release of
chemokine ligand CCL21, a CCR7 ligand.41 The complete role of chemokines and dendritic cells
in cancer cell proliferation, tolerance or destruction is not yet fully understood.
The balance of signals provided to cells and the tumor microenvironment can tip the scale
toward immunosuppression or induction of an immune response.

b) Chemokines and Metastasis
Nine out of ten cancer deaths are attributable to cancer metastases.19,42 Little is known
about the specific mechanisms of cancer metastasis. Because of its relationship to cancer
morbidity it represents an urgent need for more research. If cancer metastasis can be slowed or
halted, survival rates will greatly increase. It is known that cancer cell migration and metastasis
is not a random process, but a highly organized, complex and selective process.43 There are three
major hypotheses to explain the mechanism of metastases.44 The first implies that cancer cells
have little to no direction in migration, but can only survive in certain tissues that provide the
proper growth factors. This idea was first introduced by British surgeon Stephen Paget in the 19th
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century. Paget compared cancer cells and sites of metastasis to seeds and fertile soil.44 The seeds
will not grow in nutrient deficient soil but require nourishment from the soil. The second theory
is that the adhesion to distant endothelial luminal surface is selective only at the specific organ
site. Finally, the third proposed mechanism suggests that receptors on the neoplasms direct the
migrating cancer cells to follow a gradient of soluble factors (chemokines) to the tissue
producing these attractants.44 Evidence exists to support each hypothesis. It seems that at least
the first and third hypothesis need not be mutually exclusive, if it can be imagined that the seed
is directed to the fertile soil (by chemokines).
There are several interdependent steps in the metastatic process, beginning with the
successful growth of the primary tumor. It is unknown what causes a primary tumor to undergo
metastasis, though it is thought hypoxia might play a role in some cancers.44 Next neoplastic
cells must detach and invade either blood vessels or lymphatic vessels which requires
degradation of the extracellular matrix (ECM) and a change in morphology of the cell.32
Neoplasts then follow a pattern that closely resemble leukocytes trafficking by exiting the
vasculature and homing to distant organs.32 Finally, development of a pro-tumor
microenvironment in the new site forms a deadly metastasis. The same factors critical for growth
at the primary site also influence secondary site success but even more so as the cells are in a
foreign tissue and must be provided with stimulatory signals from the tumor microenvironment.
To get from one tissue to another involves a host of signals, some of which are provided by the
chemokine system.
In order for a neoplastic cell to leave the primary tumor site, the extracellular matrix must
be degraded by secreted proteases such as matrix metalloproteinases (MMP). In the “counter-
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current invasion” hypothesis, Opdenakker et al. proposed that the invading leukocytes, attracted
by tumor-secreted chemokines, degrade the ECM on their way to the tumor microenvironment in
a way that clears a path for the tumor cells to then reach the blood or lymph vessels.45
Overexpression of CXCL8 in PCa resulted in expression of MMP-9, which in nude mice,
increased PCa invasiveness and metastatic potential.46 In breast cancer, increased CCL5/
RANTES expression also upregulates MMP-9, furthering disease progression.32 Degradation of
the basement membrane is an early step in the metastatic process.
Cancer cells have a proclivity to metastasize to particular secondary sites. That
chemokines play a role in this predilection was first noted in breast cancer in 2001.47 Homey et
al. reported that the chemokine receptors CCR7 and CXCR4 were highly expressed by breast
cancer cells, both in the primary site and metastatic sites and showed that the ligands for the
overexpressed receptors, CXCL12 and CCL21, had highest expression in the tissues where the
most common breast cancer metastases are found, such as the lung and liver. Blocking the
CXCL12 binding site on CXCR4 with a receptor antibody led to a decrease in metastasis in a
murine model showing a relationship between this receptor on the tumor cells and their directed
metastasis.47 Since this discovery, several other chemokine ligand/receptor pairs have been
implicated in metastatic homing. Whether these chemokines direct migration over very long
distances has yet to be determined but it remains that the overexpression of chemokine receptors
is characteristic of many cancers.48,42
In summary, chemokines and their receptors have been extensively studied and play
many diverse and sometimes opposing roles in the progression of cancer. The manipulation of
the chemokine/chemokine receptor system may be useful in treating cancer.
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2.3 The Chemokine/Chemokine Receptor System in Cancer Therapy
The chemokine system is clearly involved in many steps of neoplastic growth, spread,
and evasion of the immune system. There are different points in the timeline of a neoplastic
growth where exploitation of the chemokine/chemokine receptor network may lead to
suppression of growth, activation of immune response, and inhibition of metastatic spread. The
introduction of chemokines to recruit effector immune cells and the antagonism of chemokine
receptors to block tumorigenic properties of chemokines are both possible ways to manipulate
the chemokine system.
There are instances when chemoattractive chemokines can recruit effector T-cells to the
cancer cells or induce anti-tumoral immune responses through dendritic cells. Injecting
intratumoral chemokines can disrupt the balance between immune suppression and activation
mediated by chemokines and TILs. For example, CCL5/RANTES was shown to direct effector
T-cell recruitment after injection into tumors.46 In fact, many chemokines can delay or halt tumor
progression in experimental models when injected into tumors.43 Some of these chemokines act
by recruiting dendritic cells (DC), like CCL19, CCL20, and CCL21.38,43 Properly activated DCs
can present tumor antigens and activate immune responses against the tumor. Changing the
balance of CKs can disrupt immunotolerance and activate proper host inflammatory response.
Overexpression of chemokine receptors is seen in many human tumors. Antagonism of
these receptors has already shown promise in blocking metastases; CXCR4 antagonism blocked
CXCL12 directed breast cancer metastases.39,47 There are a few different methods of antagonism
that have been tried to date, including development of chemokine receptor antibodies,
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modification of endogenous chemokines and design and development of small molecule
chemokine receptor antagonists. Antagonism of chemokine receptors is currently being
investigated for not just cancer therapies, but also for treatment of multiple sclerosis, HIV,
rheumatoid arthritis, and chronic obstructive pulmonary disease.7 As GPCRs, chemokine
receptors belong to a highly exploited class of receptors for drug targets; nearly 50% of currently
marketed drugs target GPCRs in vivo.9 The introduction of Met-CCL5, a RANTES derivative
with antagonistic effect on CCR5, into a murine model of breast cancer led to a reduction of TIL,
especially TAM, and reduced the growth of the tumor models.38 Monoclonal antibodies of
CXCR4 have also been found to inhibit lung metastases of a murine melanoma and prostate
cancer metastases to the bone in a murine model49 in addition to earlier findings that CXCR4
antibodies inhibit incidence of breast cancer lung metastases.43 High throughput screening of
small molecule libraries has produced new leads for the development of chemokine receptor
antagonists. Thus far, only one chemokine antagonist, Maraviroc, a CCR5 antagonist, has been
approved by the FDA.7 Maraviroc is used as an HIV-1 entry inhibitor. CCR5 is currently being
explored also as a target in PCa progression.

4. CC Chemokine Receptor 5 (CCR5): Structure, Function, and Antagonists
CC Chemokine Receptor 5 (CCR5) is of particular interest because of its involvement in
HIV-1 entry7 and a later discovery that a CCR5 antagonist inhibited proliferation of PCa cells.10
CCR5 is also implicated in the pathogenesis of many immune and inflammatory conditions,
including multiple sclerosis, rheumatoid arthritis (RA), psoriasis, atherosclerosis, and chronic
hepatitis.50 CCR5 is normally expressed on resting effector T-cells, monocytes, macrophages and
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immature dendritic cells.7 The endogenous ligands for CCR5 include CCL3, CCL4, and CCL57
though other chemokines have been shown to bind CCR5 at higher than physiological
concentrations.35 Like other CC chemokines, CCR5 has 4 cysteine residues in its exracellular
regions, a conserved DRYLA amino acid sequence in the second intracellular loop which is
thought to be necessary for G protein binding.7 (Figure 1) CCR5 shares the highest homology
(71%) with CCR2. CCR5 is comprised of 352 amino acids and coded on chromosome 3p21.7
CCR5-!32 is a genetic variant of CCR5 where 32 base pairs are deleted, translating into a
truncated protein which is not expressed at the cell surface. Individuals with this gene variant are
resistant to M-tropic HIV-1. High-throughput screening yielded several hits which further
resulted in new leads from several companies. Development of CCR5 antagonists has led to the
marketing of Maraviroc, a selective small molecule antagonist. Maraviroc is the only chemokine
receptor antagonist to successfully complete clinical trials.7 One of these leads, TAK-779, was
found to inhibit proliferation of PCa cells.10
The activation of CCR5 by endogenous ligands involves many effector proteins inside
the cell and can result in increase of intracellular free Ca2+ concentration, inhibition of adenylyl
cyclase and activation of MAP kinase and Jun-N-terminal kinase (JNK)51 resulting in
transcription of genes that effect T-cell proliferation and activation of cytokines.7 There is a
proposed two step process in chemokine binding, where sulfated tyrosines on the N-terminus
attract the core of the chemokine to the extracellular terminus and extracellular loop 2 (EL-2) of
the receptor followed by an interaction of the N-terminus of the chemokine with the "-helical
transmembrane domains of the receptor.7 CCR5 is generally believed to be coupled to G"i but
research has shown different chemokine ligands exhibit biphasic response curves which could
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indicate a change in G protein coupling.35 Other experiments have demostrated that in lipid rafts
with low cholesterol levels CCR5 can signal through pertussis toxin insensitive pathways.51

Figure 1. 2-D structure of CCR5 with palmitoylation sites and two disulfide bonds.

After ligand binding, the G" subunit dissociates from the G!$ subunits. G"i inhibits
adenylyl cyclase and slowly hydrolizes GTP to GDP. The activity of the G!$ is important for
chemotaxis of the cell.36 G!$ activates phospholipase C ! (PLC!) isoforms. PLC! activation
results in increased levels of diacylglycerol (DAG), inositol(1,4,5)triphosphate, and calcium ion.
G!$ signalling results in cell motility through Pyk-2 and JNK.34 CCL5 activates RhoA, which is
among many small GTPases that affect actin polymerization, cell motility, and polarity. Counterregulatory mechanisms are initiated through DAG stimulation of protein kinase C (PKC) which
facilitates C terminal phosphorylation, increasing affinity for !-arrestin binding.7
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Signaling of CCR5, like other GPCRs, is terminated by receptor internalization followed
by either recycling or degradation. The chemokine ligand is not always released through
internalization and recycling back to the cell membrane, resulting in further signaling. Two serine
phosphorylation sites are necessary for arrestin binding followed by receptor endocytosis in
clathrin coated pits.7 Dephosphorylation followed by palmitoylation of the conserved cysteine
residues can direct the protein back to the cell surface. Phosphorylation-deficient cells can also
internalize CCR5 through caveloae. Palmitoylation of the cysteine residues while the protein is
expressed on the cell surface may direct the receptor towards cholesterol rich areas of the lipid
bilayer.7 Resensitization brings the ligand binding-receptor signaling cascade full circle.
The involvement of CCR5 in HIV-1 pathology prompted a rapid and extensive search for
antagonists. Pharmaceutical companies including Pfizer, Schering, Astrazeneca, Takeda,
andGlaxoSmithKline all had a CCR5 antagonist drug candidate undergoing clinical trials as of
2008. All candidates were HIV entry inhibitors expect for Aztrazeneca, which was testing a drug
for rheumatoid arthritis.7 All candidates were optimized leads from high-throughput screening.
Maraviroc (Figure 2) was the only approved small molecule chemokine receptor antagonist to
complete clinical trials with success. TAK-779 (Figure 2) was a precursor to the Takeda drug
candidate in clinical trials. It was found to inhibit prostate cancer cell lines. Screening of natural
product extracts has resulted in the discovery of anibamine, a high affinity antagonist of
CCR5.11,12 (Figure 2)
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Figure 2. Structures of CCR5 antagonists-Maraviroc, TAK-779 and Anibamine.

C. Natural Products and Drug Discovery
Terrestrial plants, microorganisms and marine life provide an abundance of molecules
with the potential for biological activity in the human body. High throughput screening hits of
natural products as well as traditional medicine have provided drug candidates for anticancer
activity, perhaps most notably taxol and camptothecin.52 These natural products often have novel
mechanisms of action and provide unique chemical structures as new leads for drug
development, especially compared to synthetic libraries created by combinatorial chemistry.
Though combinatorial chemistry has gained popularity as a source of new leads, it has not
produced the results expected while natural product research has been deemphasized by major
pharmaceutical companies in recent years.53 The study of natural products, their structures,
biosynthesis, and mechanisms of action, have benefitted medicine, synthetic organic chemistry,
biology and will continue to be important in medicinal chemistry and drug development.
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1. Natural Products and Their Target Proteins
The majority of the natural products useful as new drug leads are secondary metabolites.
Primary metabolites are produced to maintain the normal basic functions of the cell or organism.
Secondary metabolites are produced by pathways turned on for alternate functions such as
defense from predation, disease, and starvation.54 Dixon et al. suggested that secondary
metabolites are purposed to interact with and manipulate macromolecular targets.55 For example,
many alkaloids are produced by plants to protect them from being eaten by animals. These
compounds, including morphine, nicotine, and quinine, (Figure 3) have developed to bind to
animal, mainly mammalian, proteins. Snake venom binds mammalian ion channels in nerve
cells, rendering paralysis or death. The bacterial and fungal organisms responsible for the
production of natural products like cyclosporin, FK506, and rapamycin probably intended to
utilize them for protection, instead they are used to sustain immunocompromised patients.56
These secondary metabolites must be manufactured in the cell by proteins from ostensibly the
same building blocks as primary metabolites.

Figure 3. Structures of natural products-nicotine, quinine, and morphine.
A corollary to the idea of the biosynthesis of these natural products is that, to be
synthesized by proteins, they must be bound to protein catalysts, which is the second key point in
understanding the usefulness of natural products as drug leads. A small molecule may bind one
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or more domains on a given protein as a part of a biosynthetic pathway. A domain is defined as a
part of the protein that folds independently from other parts, like an " helix or a # sheet.
Although the total number of proteins is currently unknown, it is accepted that the number of
different domains will be much smaller, estimates range from less than one percent of the
number of different proteins to half.56 With such a relatively low number of possible domains, it
is likely that molecules can be promiscuous in their binding, even across species, especially
given that among all species there are many protein types that possess the same or similar
function.54 A protein family can no longer be defined by only sequence homology or similar
catalytic activity, the arrangement of the domains in the three dimensional structure must be
taken into consideration as those domains may bind to the same or similar ligands.56 In the
future, it may be possible to predict ligands based on domain homology even though the function
of the protein is unknown. Protein catalysts bind and synthesize the secondary metabolites of
lower organisms that can bind to protein domains in other organisms.

2. Structural Attributes of Natural Products
Another virtue of natural products is their structural qualities. Natural products differ
from synthetic molecules in their complexity. In general, natural products have more stereogenic
centers, more carbon, hydrogen, and oxygen atoms and less nitrogen, sulfur and halogen
containing groups than synthetic molecules.57 Also, in violation of Lipinski’s “rule of five” for an
ideal drug candidate, often natural products have a molecular weight of greater than 500 daltons.
Structural constraint is built into natural products through extensive conjugation, fused ring
systems, and macrocyclizations; only 20% of natural product ring systems are accounted for in
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current drugs. Entropic loss upon binding to target macromolecule is minimized by these
constraints which allows for higher binding affinity allowing them to function as potent
ligands.57 Functional groups on natural products often are beyond the scope of an average
chemist’s imagination like the enediyne of calicheamicin and the carbolamine group in
ecteinascidin57 The enediyne functional group, (Figure 4) when triggered by redox reactions in
other parts of the molecule, forms a diradical intermediate that can damage DNA and produce
cytotoxicity at a concentration of one molecule per cell. In ecteinaschidin, the carbolamine group
(Figure 4) is dehydrogenated to an iminium ion and forms a covalent bond with DNA. Other
natural products produce non-covalent interactions by mimicry of shape or polarity of
endogenous ligands. Tetraguanine fragments on telomeres are imitated by telomestatin which has
eight heterocycles combined into a macrocycle, inhibiting the function of telomerases.57 Often
natural compounds have excellent pharmacokinetics because they were engineered to locate and
bind target compounds in other organisms.56 Non-intuitive compositional features make natural
products excellent sources of novel structures.

Figure 4. Examples of reactive functional groups in natural products.
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3. “Privileged Structures”
Taking these points together, the concept of a privileged structure becomes relevant. The
term privileged structure was first used by B.E. Evans and his group in describing the ability of
benzodiazepine analogues to bind many different receptor types with high affinity.58 Natural
products can be viewed as privileged structures when they both bind their biosynthetic proteins
and one or more target proteins as well. Privileged structures make an excellent starting point for
combinatorial synthesis of natural product-like libraries.
Natural product research was neglected in favor of combinatorial chemistry in recent
years. However, combinatorial chemistry has been a slight disappointment in the drug
development world. Newman et al. reported that from 1981 to 2002, there were 79 new chemical
entities for anti cancer therapies. Fourteen were peptide in nature and 48 were small molecule
natural products, analogs or mimetics. Only 17 were synthetic with no basis in natural
products.53 The problem with combinatorial chemistry is that the underlying structures for the
libraries are not biologically relevant. As Mann observed, “nature has already carried out the
combinatorial chemistry,” natural products can serve as leads for building biologically relevant
libraries.59 Libraries based on privileged structures have already proven to be fruitful, such as the
nakijiquinones by Waldmann and group and the sarcodictyins by Nicolau and group. By using
biologically functional scaffolding, both combinatorial chemistry and natural product chemistry
can benefit each other, while increasing the production of active compounds.59

4. From Traditional Medicine to the NCI Cancer Panel
Traditional medicine has relied upon various natural products to treat illness and injury
for millennia. In the area of anti-cancer research alone, nine natural product based compounds
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have been approved for cancer chemotherapy in the US as of 2008.60 These include vinblastine,
vincristine, etoposide, teniposide, taxol, navelbine, taxotere, topetecan, and irinotecan.
Two currently approved chemotherapeutics were developed from a natural product used
medicinally by Native American populations. Etoposide and teniposide are derived from
podophyllotoxin (Pd), which is an extract from the plant mayapple, Podophyllum peltatum. Skin
cancers and venereal diseases were treated with extracts from the mayapple by Native
Americans,59 but Podophyllotoxin failed the FDA’s Phase I clinical trials in the 1970s. Due to the
poor bioavailability and drug resistance of podophylotoxin,analogs etoposide and teniposidewere
synthesized. Etoposide is a Topoisomerase II inhibitor, while podophyllotoxin binds tubulin
reversibly, resulting in inhibition of microtubule assembly.61 From the traditionally used
podophyllotoxin came two anticancer agents with different mechanisms of action.
Another class of anticancer compounds are known as vinca alkaloids from the genus
Caranthus. Native populations of the West Indies and Madagascar used Caranthus rosea
medicinally for various ailments.61 Vinblastine and vincristine treat Hodgkin’s lymphoma and
acute childhood lymphoblastic leukemia respectively but with many side effects including
peripheral neuropathy, constipation and hair loss. Structural modification has led to analogs that
can treat non-small cell lung carcinoma and advanced breast cancer.61 Pharmacological
improvements of another traditionally used natural product has led to new therapies for a variety
of cancers.
The discovery that these folk medicines had anticancer affects inspired the National
Cancer Institute to begin screening natural product extracts for cytotoxicity. From 1960 to 1982
nearly 35,000 plant samples were tested against mouse leukemia cell lines.59 These screenings
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led to the discovery of taxol, which is currently estimated at producing two billion dollars
annually for Bristol-Myers-Squibb. In 1985 the NCI instituted a panel of 60 human cancer cell
lines including solid tumors and leukemias for a more thorough testing of natural products.59

5. From extract to drug candidate
After a hit is identified on the NCI screening panel, or a similar discovery of cytotoxic
activity, there are many steps to produce an FDA approved chemotherapeutic agent or even a
compound available for evaluation by medicinal chemists. There are three major obstacles in
finding a new lead: identification of duplicates, characterization, and supply. The “supply
problem” in natural product drug discovery is frequently due to natural source limitations. For
example, four thousand Pacific Yew trees were sacrificed for a mere 360 g of taxol to perform
early tests.59 Potier and colleagues overcame this his problem by using the European Yew tree
needle’s 10-deacectylbaccatin III as a starting point for the semi-synthesis of taxol in 80% yield.
Further technological improvements have ensured the continued production of taxol without use
of the Pacific yew tree. In the process of using 10-deacetylbaccatin III in the synthesis of taxol,
an analog with even better properties, taxotere, was discovered.59,62 (Figure 5) Advances in
microbial genomics as well as using the chemoenzymatic approach can help produce specific
natural products as well. The total synthesis of the natural product from simple precursors is also
an option to alleviate the supply problem.

30

Figure 5. Structures of taxanes-taxol, 10-deacetylbaccatin III, and taxotere.
Total synthesis of natural products has its roots in early synthetic chemistry. Once used to
confirm hypothesized structures, now total synthesis is useful in preparing products and analogs
for refining of the active component, lowering costs as well as a means for discovering new
chemical reactions. The first total synthesis was accomplished by F. Wohler in 1828.63 He
synthesized urea from ammonium cyanate. Later in the nineteenth century, H.E. Fischer
synthesized (+)-glucose, the first total synthesis of a chiral molecule. Throughout the twentieth
century, total synthesis schemes introduced new routes to natural product synthesis, developing a
new understanding of chemistry as well as concocting novel reactions that are now endemic in
organic synthesis. Examples include the use of protecting groups, the Wittig reaction, palladium
catalyzed C-C bond forming reactions, asymmetric catalysis and the use of “one-pot” synthetic
cascades.63 R.B. Woodward used mechanistic rationale to synthesize complex natural products
and pioneered stereocontrol in his syntheses. E.J Corey introduced the idea of retrosynthetic

31

analysis that is now is indispensable to total synthesis.63 Clearly total synthesis is a vital part of
natural product drug discovery.
Drug development also benefits from a carefully planned total synthesis approach which
can accommodate fundamental structural changes to prepare analogs via a diverted total
synthesis scheme. It is rare that the natural product produced by a given organism is the best
possible drug candidate. More often, a natural product lead provides a scaffold to build on where
drug properties can be enhanced and side effects reduced, sometimes with the added benefit of
simplifying the lead compound. Biosynthesis cannot always give these altered analogs and
building from the natural product scaffold itself (semi-synthesis) is not feasible. A diverted total
synthesis scheme can take an intermediate and build in changes in a route parallel to the original
total synthesis scheme resulting in an anolog with either more or less complexity than the parent
compound.64 A worthy example of this is the anticancer drug candidate E7389. The total
synthesis of cytotoxic Halichondrin B led to the realization that E7389, an analog missing a large
portion of the lead molecule, retained antimitotic properties and was more stable in vivo due to a
ketone functional group in place of the macrolactone of the lead compound.65 Preparation of
analogous molecules is crucial to refining the active components, which may include molecular
modeling, metabolism and mechanism of action investigations as well as structure-activity
relationship studies. With the refinement of the pharmacophore, drug development can then
address toxological, production, and formulation concerns.

6. Camptothecin and Taxol as Models for Natural Product Drug Discovery
Two important examples of natural product drug discovery and development are taxol
and camptothecin, work which was accomplished in the labs of M. E. Wall and M. C. Wani.52
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Prompted by NCI cytotoxic screenings, they purified and characterized both compounds for their
cytotoxicity. A closer examination of the efforts made by these scientists and their colleagues can
emphasize many important aspects of using natural products as anticancer drug leads. Wall and
Wani developed the use of the bioactivity of a crude extract to guide the purification of the most
potent compound. Camptothecin, isolated from the Chinese tree, Camptotheca acuminate, led to
two first generation analogs, irinotecan and topetecan, (Figure 6) which are used for the
treatment of colon and ovarian cancers. Camptothecin itself had poor solubility and early
attempts to form it into a salt disturbed a lactone ring moiety that turned out to be necessary for
activity. Camptothecin binds Topoisomerase I, which at the time was an unknown target for
cancer therapy. Since this discovery, several other topoisomerase “poisons” have been
discovered, including etoposide and doxorubicin. Recently it was observed that camptothecins
might also target hypoxia-inducible factor 1, a protein involved in maintaining a cancer cell’s
ability to survive in hypoxic conditions and which may also be involved in metastasis. Taxol, as
mentioned previously, was discovered from the Pacific Yew tree. It has been useful in the
treatment of ovarian, breast, and lung cancers. Both taxol and its derivative taxotere have the
same mechanism of action, microtubule stabilization, another previously unknown cellular target
for anticancer drug development. Taxol and camptothecin have launched two new classes of
drugs with previously unknown targets. Both were painstakingly purified and characterized from
crude extracts of bioactive natural products and are excellent examples of the power of natural
products in drug discovery and development.
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Figure 6. Structures of camptothecin and analogs irinotecan and topetecan.
7. Influence of Natural Products on Cancer Biology
Natural product research has also had an impact on our understanding of biology. Novel
mechanisms of actions and consequently the discovery of novel targets have also been benefits
of natural product drug discovery. The discovery of taxol led to the study of tubulin stabilization
as an anti-cancer mechanism. Topoisomerase I was discovered as an anti-cancer target because of
Camptothecin.52 Frequently, cancer chemotherapeutics are used in combination with another
therapy in order to combat cancer cells that have accrued many growth and regulation
abnormalities. Also, when first line therapies fail, second line therapy is usually aimed at another
cellular target, to combat drug resistance. It is notable that many daughter compounds are used to
treat different forms of cancer from the lead natural product, multiplying the therapeutic impact
of the parent compound. In fact, some screening has changed from strictly cell based to
mechanism of action based.59 The discovery of more cellular targets is a major help in curbing
cancer.

8. Anibamine, a Natural Product Chemokine Receptor CCR5 Antagonist
In 2004, anibamine was isolated from a crude extract fron Aniba panurensis by activity
guided fractionation for its antimicrobial activity against an azole-resistant strain of Candida
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albicans,12 much like the method Wall and Wani pioneered.52 The novel indolizinium alkaloid
was tested against the DTP 60 human cancer cell lines with an LC50 of 10-5 M with no selectivity.
Anibamine was found to have a logP value of 9.1, much higher than that the maximum of five
suggested by Lipinski.12 The same compound was also concurrently isolated from an assay
involving human CCR5 receptor,

125I-gp120,

and soluble CD4 to test for CCR5 antagonism.11

The total synthesis of anibamine was established in 2005 in our lab. A ten step synthesis from
acetyl acetone and cyanoacetic acid yield anibamine and 3 isomers.14 Due to its hemolytic
activity and high logP, modification is necessary to optimize its activity and lower its toxicity.

9. Summary of Impact of Natural Products on Drug Discovery
The collective decision to slight natural product research was clearly a poor one. The use
of natural products has come a long way from primitive man. Bioinformatics and structural
biology demonstrate the possibility for promiscuity between small molecules and protein
domains; privileged structures bind different kinds of proteins with high affinities. Traditional
medicine has led to currently used and refined compounds such as the Vinca alkaloids and
campothecins. The success of folk medicines inspired the National Cancer Institute to begin
screening of natural product extracts against cancer cell lines which has produced more drug
candidates. The hurdle of producing mass quantities of biologically active compounds have been
largely overcome by pioneering of synthetic chemistry methodologies. The study of natural
products has also benefitted the field of biology by contributing to the elucidation of novel
mechanisms of action that has led to new insights in understanding disease targets. The currently
undiscovered natural products of the world will certainly yield even more insight in many fields.
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III. Project Design and Objectives
The chemokine receptor CCR5 has been implicated in a number of disease states,
including HIV-1 and prostate cancer. Because of the wide variety of applications, antagonists of
CCR5 are highly sought after. High throughput screening of synthetic libraries have resulted in
several drug leads, but only one successful drug has emerged thus far. The realm of natural
products should not be overlooked when looking for biologically active lead compounds as
antagonists for this receptor.
Anibamine was discovered as a novel natural product with a high binding affinity for
chemokine receptor CCR5. However, its pharmacological properties were not ideal. The
lipophilicity of the molecule exceeded the guidelines envisioned by Lipinksi. Anibamine also
possessed considerable toxicity.

In order to refine the active structure and increase the

therapeutic index, the structure activity relationship of anibamine needed to be established. This
was to be accomplished by synthesizing analogs using the “Deconstruction-ReconstructionElaboration” approach. This method was applied by “deconstructing” functional groups and
atoms of the lead compound sequentially. Following this, “reconstruction” of the molecule
rebuilt the parts of the molecule in a different order. Ideally this would give the pharmacophore,
the core of the molecule necessary for its biological activity. To the defined pharmacophore,
“elaborations” can be made by the addition of atoms or groups of atoms or altering of
stereochemistry. As a natural product, anibamine offered a unique scaffold for modification.
There are several points in the structure of anibamine that can be deconstructed and/or
elaborated upon. The proposed structural modification of anibamine are shown in Figure 7. At
point (a) the sidechains can be deconstructed. The sidechain double bond configuration can be
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elaborated upon at point (b). Elaboration of the ring at part (d) has been accomplished in our lab
and deconstruction of the ring at point (c) is ongoing. These modifications were each intended to
further refine the pharmacophore of this series of coumpounds.

Figure 7. Proposed structural modifications of anibamine

Figure 8. Structure of anibamine, 1a, and proposed deconstructed analogs 1b and 1c.
The purpose of this project was to synthesize and characterize anibamine (1a) and two
deconstructed analogs (1b and 1c). (Figure 8) The analogs were to retain the indolizinium core
structure of anibamine but retain only one of the aliphatic side chains at C-8 or C-6. Synthesis of
deconstructed analogs paralleled the total synthesis of anibamine (Scheme 1) with different
starting substrates. Synthesis and evaluation of deconstructed analogs would answer the question
of which sidechains were important for activity, or whether of not both were critical for activity.
The synthetic route yielded two isomers and upon hydrogenation, a third analog. The synthesis
and evaluation of analogs with different bonds at point (b) would give elucidate what
configuration is ideal and if a saturated bond is best, this would facilitate more efficient
synthesis.
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Scheme 1. Total synthesis of anibamine (1a) from acetylacetone. Reagents and conditions: i.
cyanoacetic acid, K2CO3, H2O, overnight; ii. 1)NBS, H2SO4, TFA, 0˚C 2 hours; 2) CuCN, DMF,
N2, reflux 48 hours; iii. TBAB, P2O5, toluene 90˚C, 2 hours; iv. CuI, PdCl2(PPh3)2, 10, Et2O; v.
55 psi H2, Pd/C, MeOH, 7 hours; vi. 1) DIBAL-H, toluene -78 ˚C, 2 hours; 2) H2SO4 (aq); vii. 1)
14, LHMDS, toluene -78 ˚C, 2 hours; 2) NH4Cl (aq) (R=-CH=CH(CH2)7CH3); viii. 1N HCl,
EtOH, reflux 5 hours; ix. MsCl, TEA, CH2Cl2 0˚C to rt, 1 hour

In addition to the preparation of analogs, sidechain coupling reactions were explored in
order to discover if there was a way to more efficiently synthesize geometric isomers of interest.
The original total synthesis scheme used the Wittig reaction to attach the aliphatic sidechains to
the aldehyde intermediate. This reaction results in primarily cis double bonds in the product.
While this was desired to produce anibamine, it also made separation of pure product tedious and
expensive by HPLC. To continue to investigate analogs of anibamine, a stereoselective synthesis
of only one isomer was desired. Different methods were attempted to yield only the trans isomer
with varying results.
After the synthesis of the analogs, biological assays were performed to develop structure
activity relationships. Previously prepared analogs and deconstructed analogs were evaluated to
answers questions of sidechain, ring size, and double bond configuration importance. Three
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metastatic prostate cancer cell lines, DU-145, PC-3, and M12, were used in anti-proliferative
assays with each drug. The colorimetric agent, WST-1, was used in each screening. The goal of
the assays was to determine the next generation lead compound for anti-prostate cancer activity.
Ligand docking experiments were performed using two homology models of CCR5
based on two different crystal structures of other GPCRs. Can these homology model
differentiate between the very similar deconstructed analogs? These were performed to analyze
possible binding modes of the deconstructed ligands within the binding pocket of CCR5 and to
continue to scrutinize the validity of the different models.
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IV. Results and Discussion

A. Chemical synthesis of Anibamine and Analogs as CCR5 Antagonists
The total synthesis of anibamine was accomplished in our lab previously.13 To prepare
anibamine and the deconstructed analogs, three key intermediates, 2a, 2b, and 2c were
synthesized. (Figure 9) From preparation of these intermediates, parallel synthetic routes
produced anibamine and analogs 1b and 1c along with their trans isomers.

Figure 9. Key intermediates in each synthetic pathway, 2-hydroxy-4,6-dimethylpyridine-3,5dicarbonitrile (2a), 2-hydroxyl-4,6-dimethylnicotinonitrile (2b), and 6-hydroxyl-2,4dimethylpyridine-3-carbaldehyde (2c),

1. Synthesis of key intermediates in each route
Two synthetic routes to 2a in the total synthesis of anibamine were previously reported.
Route 1 (Scheme 2) began with the condensation of acetyl acetone and N,N-dimethylformamide
dimethyl acetal in neat refluxing conditions.66 Product 3 was purified by recrystallization in
EtOAc with 71% yield. In an acid catalyzed reaction, 4 was prepared using hydroxyl amine
hydrochloride in MeOH at reflux.67 The isoxazole product was purified under reduced pressure
distillation affording 4 in 51% yield. Compound 4 was then refluxed neat with 3 equivalents of
aniline, followed by an acidic workup.68 Recrystallization in EtOH afforded 5 in 54% yield. The
#$enaminonitrile (5) was then dissolved in MeOH with KOH and malononitrile at reflux. The

40

basic conditions cleaved the aniline group ultimately resulting in the first intermediate, 2a, in
74% yield.69

Scheme 2. Route 1 to the first intermediate in anibamine synthesis. Reagents and conditions: i.
N,N-dimethylformamide dimethyl acetal, reflux; ii. HONH2HCl, MeOH, reflux; iii. PhNH2,
reflux iv. Malononitrile, KOH, MeOH, reflux.
In route 2, the first step (Scheme 3) was condensation of cyanoacetamide and acetyl
acetone in a potassium carbonate solution of approximately pH = 9 at room temperature
overnight.70 The product 2b forms a precipitate in 91% yield. Compound 2b is also the first key
intermediate in the synthesis of anibamine analog 1b. Bromination at the 5-postion of the
pyridine ring with NBS in acidic conditions yielded 5-bromo-2-hydroxy-4,6dimethylnicotinonitrile in 71% yield.71

Scheme 3. Route 2 to the first intermediate in anibamine synthesis. Reagents and conditions: i.
Cyanoacetamide, K2CO3, H2O, rt; ii. NBS, TFA, H2SO4; iii. CuCN, DMF, N2, reflux.
The next step proved to be the most difficult step in the synthesis of 2a mostly due to its
workup. In the Rosenmond-von Braun reaction, CuCN supplied the nucleophile for nucleophilic
aromatic substitution of the bromide at the 5 position on the pyridine ring. CuCN is used in 20%
excess with DMF as solvent at reflux.72 The reaction turned to dark brown over 48 hours at
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reflux under N2 protection. At this point no starting material would show on a TLC plate. The
mechanism of the reaction involves a copperIII complex being formed in an oxidative addition
step. (Scheme 4) To reduce this complex, aqueous ferric chloride (FeCl3 in H2O and HCl) was
used. Attempts to neutralize this acidic solution before extraction created large amounts of
precipitate which generally trapped the product. The best method of purification was to rinse the
precipitate with EtOAc multiple times to extract as much product from the inorganic salts as
possible. Also, extracting the acidic solution with EtOAc yielded some product. The crude
product was purified by recrystallization in AcOH to yield a white powder at 50% yield or less.
The mother liquor of the recrystallizations was collected to purify more product after combining
with subsequent trials.

Scheme 4. Mechanism of Rosenmund-von Braun reaction.
Due to the difficulties encountered in the traditional Rosemund-von Braun reaction an
another attempt at cyanation of aryl bromides was made. Literature search revealed a seemingly
promising domino reaction using 20% KI, 10% CuI, and 120% NaCN with a diamine ligand in
toluene.73 (Scheme 5) The rationale behind this reactions is that the aryl bromide is converted
into the more reactive aryl iodide by copper catalysis, then the aryl iodide is converted to the aryl
cyanide. Toluene was the solvent suggested in the paper by Zanon et al. because it retained the
delicate balance between aryl bromide, aryl iodide, and sodium cyanide in solution.
Unfortunately, 5 was barely soluble in toluene. Nearly 40 times the recommended amount of
toluene was necessary to dissolve the aryl bromide, which disrupted the concentration of soluble
sodium cyanide, resulting in little progress over 24 hours.

42

Scheme 5. Mechanism for copper-catalyzed domino halide exchange-cyanation of aryl bromides
Compound 2c is the first key intermediate in the synthesis of deconstructed analog 1c.
The synthesis of 2c is accomplished in two steps from cyanoacetic acid. Stoichiometric amounts
of morpholine, triethyl orthoacetate, and cyanoacetic acid were condensed in a neat reflux to
form 3-morpholinobut-2-enenitrile (7).74 (Scheme 6) This three component reaction turned out to
be rather messy and the beta-cyanoenamine was difficult to purify. In literature, it was suggested
to conduct recrystallization to purify the product but it was hardly feasible given that the melting
point for the product was around 40!. Column chromatography was the best means of
purification though reduced pressure distillation may prove even more efficient. Yields for this
reaction remained low, less than the literature value of 54%. Condensation of two molecules of 7
formed the pyridine ring intermediate 2c through an imino acid intermediate. The production of
2c was reported as an undesired product of a reaction between 7 and 4,4,4-trifluoroacetoacetate
in acetic acid to prepare a trifluromethyl substituted heteraromatic compound. Because this byproduct was described as being a self-condensation reaction of 7, 4,4,4-trifluoroacetoacetate was
not used as a reagent for our purposes to achieve a yield of 2c as the main product.75
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Scheme 6. Synthetic route to the first intermediate in the synthesis of 1c. Reagents and
conditions: i. Morpholine, triethyl orthoacetate, reflux; ii. AcOH, reflux.

2. Bromination of key intermediates
After synthesis of the key intermediates 2a, 2b, and 2c, each series of compounds
paralleled the synthetic route of anibamine. Bromination of 2a, 2b, and 2c took place in a heated
toluene solution with tetrabutylammonium bromide as the bromine ion supplier and phosphorous
pentoxide becoming a phosphate ion leaving group.76 (Scheme 7) Phosphorous pentoxide is
highly hygroscopic and in this reaction sometimes produced a sticky layer at the bottom of the
flask presumably where starting material was trapped and unable to react. TLC analysis of the
toluene layer showed no remaining starting material but yields remained low when this sticky
film was present. Lowering the reaction temperature to 85-90! from the literature suggested
value of 100! and increasing the amount of solvent improved yields. After the reaction was
completed, ice was added to the reaction. Neutralization of the water did not have much effect on
increasing yields during extraction. Recrystallization in EtOAc or column chromatography on
Al2O3 produced the pure products 2-hydroxy-4,6-dimethylpyridine-3,5-dicarbonitrile (8a), 2bromo-4,6-dimethylnicotinonitrilepyridine (8b), or 6-bromo-2,4-dimethyl nicotinonitrile (8c).
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Scheme 7. Synthetic route from key intermediate to the hydrogenation products. Reagents and
conditions: a. TBAB, P2O5, toluene 90˚C, 2 hours; b. CuI, PdCl2(PPh3)2, 10, Et2O; c. 55 psi H2,
Pd/C, MeOH

3. Sonogashira coupling
Sonogashira coupling of the bromopyridines with PMB protected propargyl alcohol was
rather straightforward. The preparation of the PMB protected propargyl alcohol involved a two
step reaction.77 (Scheme 8) Under N2 protection a catalytic amount of sodium hydride
deprotonated 4-methoxy benzyl alcohol in Et2O which then reacted with trichloroacetonitrile at
0! forming 4-methoxybenzyl trichloroacetimidate (9). The dried crude imidate was dissolved in
a solution of hexane: CH2Cl2 (2:1, v/v) and propargyl alcohol was added. The solution was
cooled to 0! under N2 protection and a catalytic amount of 10-camphorsulfonic acid was added.
The reaction was allowed to warm to room temperature overnight. Protected propargyl alcohol
(10) was purified by column chromatography for use in the coupling reaction.

Scheme 8. Synthesis of 10. Reagents and conditions: i) NaH, trichloroacetonitrile 0! to RT, N2,
4 hours; ii. Propargyl alcohol, hexane:CH2Cl2, 10-CSA 0! to RT, overnight
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Compound 10 was dissolved in Et2O before slow addition to a solution of CuI,
Pd(P%3)2Cl2, TEA, and bromopyridine in Et2O at room temperature under N2 protection.78
(Scheme 7) In Series a, the product, 11a formed a precipitate in the Et2O layer. The precipitate
could be filtered and then recrystallized in EtOH to form the pure product in 66% yield. In Series
b, the purification of 8b proved very difficult. Both chromatography and recystallization were
attempted to get a product suitable for hydrogenation. Original literature by Kenkichi
Sonogashira suggests passing the organic extract through Al2O3 followed by recrystallization in
EtOH results in complete removal of catalyst to yield pure product.79 Following this workup
procedure, 11b was purified to move on to the hydrogenation. The series c product, 11c, was
prepared without difficulty.

4. Hydrogenation of alkyne intermediates
Hydrogenation of alkynes was without complication except in the case of 11b as
menioned above. Each alkyne was dissolved in MeOH with a catalytic amount of Pd/C.13
(Scheme 7) Hydrogenation took place between 45-55 psi H2 over an average of 7 hours in yields
of 85% or higher. Alkynes 11a and 11c were hydrogenated directly to their alkane counterparts
12a and 12c. Many attempts at hydrogenation of 11b failed. At times, the alkene product was
isolated, indicating that the catalyst was poisoned. Also loss of starting material was observed.
The purity of the starting material was confirmed by TLC, melting point and 1H NMR. Finally,
when the alkyne was purified by the original Sonogashira methodology described above,
hydrogenation to 12b occurred quickly in quantitative yield.
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5. DIBAL-H reduction
After hydrogenation, each nitrile group was reduced to an aldehyde. This was
accomplished by di-isobutyl aluminum hydride (DIBAL-H) in toluene.80,81 An excess amount
DIBAL-H is capable of reducing the nitrile to its amine equivalent, which was not desired. To
avoid this, reactions were maintained at low temperatures and a minimal amount of DIBAL-H
was used. Just over two equivalents were used to reduce the dicarbonitrile to 13a at -78!.
(Scheme 9) Slightly more than one equivalent was used for the substrates 12b and 12c. (Scheme
10) The mono-nitrile substrates did not react at the low temperature of -78! so the reaction
temperature was raised to 0! to afford the reduction products 13b or 13c. In this reaction, the
lone pair of electrons on the nitrile nitrogen reacts with the aluminum atom of DIBAL-H and the
hyride ion then transfers to the nitrile carbon. Dilute sulfuric acid was used to hydrolize the
nitrogen-aluminum complex, forming the aldehyde. The reaction yields were mild, from 60% to
70%.

Scheme 9. Synthetic route from first hydrogenation product to Wittig product in synthesis of
Anibamine. Reagents and conditions: i. 1) 2.1 eq DIBAL-H, toluene, -78˚C, N2, 2 hours, 2)
H2SO4 (aq); ii. 1) 2.2 eq 14, LHMDS, toluene -78˚C, N2, 2 hours 2) NH4Cl (aq).
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Scheme 10. Synthetic route from first hydrogenation product to Wittig product in synthesis of 1b
and 1c. Reagents and conditions: i. 1) 1.3 eq DIBAL-H, toluene -78˚C, N2, 2 hours, 2) H2SO4
(aq); ii. 1) 1.2 eq 14, LHMDS, toluene -78˚C, N2, 2 hours 2) NH4Cl (aq).

Scheme 11. Synthesis of non-1-yl triphenyl phosphonium bromide (14). Reagents and
conditions: i. 1-bromononane and triphenylphosphine, toluene, N2, #, 60 hours

6. Exploration of sidechain coupling reactions
The transient nature of the aldehyde called for immediate reaction with a Wittig reagent
often without purification of the aldehyde. A phosphonium bromide salt was synthesized by
refluxing 1-bromononane and triphenylphosphine in toluene for several days.13 (Scheme 11)
After evaporation of toluene, the crude product was washed with Et2O and extensively dried
before reacting in toluene with lithium hexamethyldisalizide (LHMDS) under N2 protection
forming the Wittig reagent. After formation of the bright red phosphonium ylide, the reaction
mixture was cooled to -78! and the aldehyde in toluene was added slowly over several minutes.
Upon addition of the aldehyde, the deep red color of the reaction was reduced to yellow or
orange indicating the reaction was proceeding. After about 15 minutes at -78!, the reaction
mixture was allowed to warm to room temperature and stirred for an hour. When the reaction
was complete, addition of saturated aqueous ammonium chloride resulted in a clear solution.13
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The reaction yielded mainly the Z isomer, with some trans product at about 70% total conversion
rate.
The Wittig reaction produced both cis and trans isomers but a more direct route to the
trans isomer was desired. Several attempts at increasing trans isomer yields were made. (Table
1) Literature searched revealed a promising and seemingly uncomplicated variation of the Wittig
reaction, the Schlosser modification, that yielded predominantly trans alkenes. (Scheme 12) The
principle behind this method is that the addition of soluble lithium salts stabilize the betaine ylide
intermediate in a form that results in trans stereochemistry in the product after elimination.83 In
the first step of this reaction, phenyl lithium and lithium bromide are added to a phosphonium
bromide salt. The phenyl lithium deprotonates the "

carbon next to the phosphorous atom

resulting in ylide formation. Addition of the aldehyde causes the nucleophlic attack of the ylide
carbanion at the carbonyl carbon. The positively charged lithium ion stabilizes the betaine. A
second addition of phenyl lithium and lithium bromide deprotonates the " carbon and a lithium
atom replaces the proton thus removing the stereochemistry at this site. At this point the betaine
undergoes a spontaneous pyramidal interconversion inverting the stereochemistry at the " carbon
resulting in a predominantly threo conformation. From here, the addition of acid reprotonates the
" carbon removing the lithium. A tert-butoxide ion delithiates the oxygen, resulting in trans
alkene and phosphine oxide formation.84
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Scheme 12. Proposed mechanism for Schlosser modification of the Wittig reaction
The problem with this reaction is a matter of solubility. In the literature, diethyl ether is
the recommended solvent, with THF as a second choice. In our case the Wittig reagent, 14, is not
soluble in either solvent so a toluene/THF solution had to be used which was not ideal for the
solubility of the lithium salt. Soluble lithium salts are critical for the formation of mainly trans
alkenes. Literature suggested using “homemade” phenyl lithium as a product of bromobenzene
and lithium which results in a stoichiometric amount of lithium bromide as a sideproduct. As a
second choice, the literature recommended adding two equivalents of LiBr to the phosphonium
bromide at the beginning of the reaction before adding the commercially available PhLi in di-nbutyl ether solution which was the procedure adopted.84 Still, it seemed the lithium salt solubility
and 1-nonyl phosphonium bromide solubility were inversely proportional and more than one
equivalent of PhLi was needed to reach the deep red color of the prepared Wittig reagent. After
addition of the aldehyde another equivalent of PhLi in solution was added. However, a majority
of trans product was not observed. Percent conversion and isomeric excess seemed to be
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inversely proportional; it seemed that the longer the reaction ran, the more cis alkene and
conversion of starting material was observed. An earlier attempt was made using LiCl with 13b
as the substrate with similarly low percentage of trans isomer and percent conversion. Different
variations in conditions afforded no significant changes in cis:trans ratios.
Another method tried was to prepare the traditional Wittig reaction but heat it to reflux in
toluene for 24 hours; during the course of the reaction the cis product would be isomerized to the
more thermodynamically stable trans isomer. This method was tried with 13b as starting
material. Proton NMR revealed nearly a 1:1 ratio of products, but only 55% conversion.
Subsequently, a traditional Wittig at low temperature also resulted in an equal ratio of isomers
but with 79% converstion.
The Grignard reaction was tried also to prepare trans alkene.80,81 Both 13a and 13b were
used as starting material for different attempts. Again it appears solubility played a major role in
the progress of this reaction. 1-bromononane was added to magnesium and iodine in THF slowly
and allowed to gently reflux. (The reaction had been tried also with diethyl ether as solvent to no
avail.) In THF at reflux, It seemed that the Grignard reagent, 1-nonylmagnesium bromide, had
been formed. However when the reaction was cooled to -70! in preparation for addition of the
aldehyde, some precipitate formed. After addition of the aldehyde, no reaction took place. The
reaction temperature was raised first to 0 !, then room temperature and finally reflux, but there
was no change. One equivalent of benzaldehyde was added in attempt to determine the problem.
No reaction took place with benzaldehyde either. It was concluded that the Grignard reagent was
not formed or not soluble at low temperature.
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Table 1. Reaction conditions, yields and stereoselectivity of the various coupling reactions. The
letters a, b, and c correspond to the series of the compounds used as substrate.

Reaction Conditions

% trans

% cis

% conversion

Wittig (a)

35%

65%

73%

Wittig (b)

50%

50%

80%

Wittig (c)

38%

63%

67%

Wittig reflux (b)

50%

50%

55%

LiBr (a)

50%

50%

50%

LiBr (b-1)

25%

75%

25%

LiBr (b-2)

34%

66%

30%

LiBr (c)

16%

66%

77%

LiCl (b)

21%

71%

40%

Grignard (a)

n/a

n/a

NR

Grignard (b)

n/a

n/a

NR
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7. Deprotection and Cyclization Reactions
After the aliphatic sidechains were coupled, the para methoxy benzyl protecting group
was removed to expose the alcohol for cyclization to the final product. (Scheme13) Deprotection
was carried out in a solution of ethanol and 1 M hydrochloric acid at reflux.85 Cyclization to the
final 1H-indolizinium ion took place in dichloromethane with TEA and MsCl from 0! to room
temperature.86 The isomeric mixtures were purified first on a silica gel column with
CH2Cl2:MeOH as eluent.

Scheme 13. Synthetic route from Wittig product to final product for all routes. Reagents and
conditions: a. 1N HCl, EtOH, reflux 5 hours; b. MsCl, TEA, CH2Cl2 0˚C to rt, 1 hour.
8. Separation of isomers
As a result of the various Wittig reactions, each reaction center resulted in cis and trans
isomers. Three geometric isomers of anibamine (17a, 18, and 19) were synthesized in addition to
anibamine. (Figure 10) Trans isomers (17b and 17c) of each deconstructed target compound
were also synthesized. (Figure 11) Separation of geometric isomers was first attempted on
HPLC. Anibamine and its isomers had been previously separated on HPLC and the same
conditions were successfully repeated. For series c, HPLC separation of 1c and its trans isomer
was attempted using the conditions for anibamine as a starting point. All the peaks appeared to
come out in under 15 minutes, so the percentage of water was increased by 5% from 47.5% to
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72.5% before separation of peaks became visible after about two hours. In order to distinguish
separate peaks, the injection sample was extremely dilute. Continued separation at this
concentration was not feasible and higher concentrations were not separable so alternate methods
of separation were explored.

Figure 10. Geometric isomers of target compounds. (X- = TFA- or Cl-)
Since silver nitrate has been reported to separate isomeric fatty acids on prep TLC plates,
a brief investigation of AgNO3 prep TLC was carried out. The cis and trans double bonds are
supposed to form different strength bonds with the silver ions embedded on the silica gel
resulting in greater separation of isomers. Different ways of preparing the plates exist in
literature, for this the plates were developed in a solution of AgNO3 dissolved in MeCN. In fatty
acid separation, Rhodamine 6G, a fluorescent indicator, is used to visualize the bands but this
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would not work for the compounds in this research. Due to poor visualization and
inconsistencies between plates, this option was ruled out. Separation was attempted on prep TLC
plates without AgNO3 with poor results. A mixture of 1c and its trans isomer, 17c, was
developed up to 7 times in CH2Cl2:MeOH (25:2, v/v). Three bands were collected and
characterized by 1HNMR but no desired pure isomers were observed. It was concluded that the
acidity of the prep TLC plates was causing some degradation of the sample. For series b, the
separation of the deprotected products, 16b and its trans isomer, was attempted on prep TLC.
Two bands were present after 3 developments in hexane/ethyl acetate (2:1, v/v) solvent system.
The top band was pure cis isomer but the lower band contained a mixture of both isomers, with
trans present in the majority. After cyclization, separation of the mixed product was attempted
but with the same poor results as in the series b. For the mono sidechain analogs only 6-dec-1Zenyl-5,7-dimethyl-2,3-dihydro-1H-indolizinium chloride (1b) was purified from its isomer.
Hydrogenation of the mixtures yielded a saturated analog for each series. (20a, 20b and 20c)
(Scheme 14) All of the final compounds were characterized by proton and carbon nuclear magnetic
resonance spectroscopy (NMR) and mass spectrometry (MS).
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Scheme 14. Synthesis of hydrogenated final products. Reagents and conditions: i) 55 psi H2, Pd/C,
MeOH, 8 hours.

In conclusion, six new analogs of anibamine were synthesized following the diverted total
synthesis scheme. Efforts to stereoselectively synthesize of trans isomer were not very successful
though in some instances the percentage of trans in the final product was increased. All the attempts
to synthesize trans analogs were based on an aldehyde starting material. This starting material was
used because the rest of the synthetic scheme had been previously worked out as had the separation
of anibamine and its geometric isomers. Other synthetic routes are currently being explored in our
lab to improve stereoselectivity. If selectivity is increased, then the separation issue becomes less
important. For now, prep TLC separation of the deprotected analogs seems most promising.
Separation of the anibamine isomers was possible because of a combination of higher molecular
weight and greater differences between isomers because of the two double bonds. The compounds

56

with only one sidechain were less different from each other and not easily separable. Any reactions
that lead to only one isomer will negate the need for an isomeric separation process.

Figure 11. Strucutres of all synthesized compounds. (X- = TFA- or Cl-)
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B. Anti-proliferative assays of Anibamine and analogs

Anti-proliferative assays of anibamine and its analogs were performed against various
aggressive prostate cancer cell lines to determine structure-activity relationships and to help
define a next generation lead compound. Three cell lines, PC-3, M12, and DU-145, were in this
assay. Previous data suggested that a 72 hour drug incubation time resulted in the best dose
dependent effect (data not shown). Some deconstructed analogs of anibamine were also tested at
24 and 48 hours. Cells were plated 103 cells per well on 96 well plates with a volume of 100 µL
media containing 1% L-glutamine, 0.1 % ITS (insulin, 5µg/mL; transferrin, 5µg/mL; and
selenium, 5 µg/mL) and 0.1 % gentamicin. The media for M12 cells contained 5% fetal bovine
serum (FBS); media for DU-145 and PC-3 contained 10% FBS. Twenty-four hours after plating,
different concentrations of drug were added to a total well volume of 150 µL and the cells were
incubated for a further 24, 48 or 72 hours. After the allotted time interval the media was
unceremoniously removed and serum free media was added to each well to a volume of 100 µL.
Ten µL of the anti-proliferative reagent WST-1 was added and the cells incubated a further 3
hours before the absorbance of each well was read by an ELISA at 450 nm. WST-1 is a
tetrazolium salt that is cleaved by mitochondrial dehydrogenases into a water

Figure 12. Metabolic cleavage of WST-1 into soluble formazan dye. RS:mitochondrial
reductase, EC: electron coupling reagent87
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soluble formazan dye that is dark red in color. (Figure 12) The viable cells contain active
mitochondrial dehydrogenases which increase production of the formazan dye thus increasing
absorbance of each well with viable cells. 87
The drugs used for this assay were anibamine and analogs containing 5-, 6-, or 7membered rings fused to the pyridine ring synthesized in our lab. (Figure 13) Compounds 21, 22,
and 23 have a 6-membered fused ring. Compounds 24, 25, and 26 have a 7-membered fused
ring. For each group of compounds with a common ring size, there is also a trans, trans, cis, cis,
and saturated analog. Also compounds 1b, 20b, and 20c were tested from series b and c and
mixtures of cis and trans isomers of each set of deconstructed analogs. The IC50 values for the
twelve purified compounds are presented in table 2. Comparisons can be made by ring size and
double bond configuration for the first nine compounds. Among deconstructed analogs, further
scrutiny will determine which sidechain might be more important for anti-proliferative activity
and if the double bond plays a role. Variations among activity in each cell line is indicative of
CCR5 expression differences. Vaday, et al. reported that DU-145 expressed more cell surface
CCR5 than PC-3.10 J. Adams showed that M12 expressed significantly more CCR5 than either
other cell line.13 Because of differences among each cell line, structure-activity relationships are
discussed for each cell line.
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Figure 13. Structures of Anibamine and eleven analogs tested for anti-proliferative activity.
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Table 2. Half maximal inhibitory concentration (IC50) of 12 compounds in three cell lines at 72
hours.

IC (nM)

Compound

IC (nM) M12

Anibamine

1.8 ± 1.7

172.5 ± 41.0

898.3 ± 75.1

17a

5.9 ± 1.5

63.0 ± 14.9

409.1 ± 48.4

20a

9.0 ± 6.3

155.1 ± 103.4

364.2 ± 22.8

21

5.9 ± 3.7

212.5 ± 30.5

187.1 ± 35.0

22

> 1,000

> 5,000

> 2,000

23

21.1 ± 15.4

371.0 ± 38.7

271 ± 61.6

24

8.1 ± 6.8

336.2 ± 82.1

158.7 ± 62.9

25

2.4 ± 2.2

256.4 ± 61.5

170.8 ± 89.6

26

1.2 ± 1.1

156.1 ± 47.5

317.6 ± 30.4

1b

5.9 ± 1.9

422.9 ± 63.0

22.7 ± 19.7

20b

142.7 ± 83.6

189.1 ± 60.4

618.0 ± 92.26

20c

2.6 ± 2.1

159.9 ± 36.3

9.55 ± 7.2

50

50

DU-145

IC (nM) PC-3
50
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1. Anti-proliferative activity of Elaboration products on PC-3 cell line
The PC-3 cell line had the least response to the drugs, but was still inhibited to an extent.
This is consistent with its lower expression of CCR5 compared to the other cell lines.
Compounds 24, 25, and 26 all have 7 membered rings fused to the pyridine. 24 had the highest
activity of the nine compounds with two sidechains (Figure 14 and) 25 had the highest activity of
all compounds with two trans double bonds and 26 had, within standard error, the highest
activity of the saturated analogs with two sidechains. Figure 15 depicts the structures of all cis,
cis compounds and their IC50. For this cell line, the 7-membered ring compounds had the highest
activity of all compounds with two sidechains. The double bond configuration seems to be less
important than ring size in the PC-3 cell line.

24 in PC-3

% inhibition of proliferation

120.00%

90.00%

60.00%

30.00%

0%
10 uM

1 uM

100 nM

10 nM

[24]

Figure 14. Percent inhibition of PC-3 cell line by 24 at four concentrations.
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Figure 15. Structures and IC50 of 24, 21, and 1a.

2. Anti-proliferative activity on DU-145 cell line
The DU-145 cell line was the fastest growing cell line. The E,E-geometric isomer of
anibamine, 17a, had the lowest IC50 value in this cell line, the only IC50 value under 100 nM.
(Figure 16) Anibamine (1a) had the highest activity of all compounds with cis double bonds.
Compound 20a had, within standard error, the highest activity of the saturated analogs with two
sidechains. For DU-145 the 5-membered ring compounds had the highest activity. Figure 17
depicts the structures of all trans, trans compounds and their IC50. Comparing double bond
configuration for each group of compounds gives no indication of activity. Ring size seems to be
the most important structural feature in this cell line.

63

17a in DU145

% inhibition of proliferation

110.00%

82.50%

55.00%

27.50%

0%
10 uM

1 uM

100 nM

10 nM

[17a]

Figure 16 Percent inhibition of DU-145 cell line by 17a at four concentrations.

Figure 17. Structures of 17a, 22, and 25.
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3. Anti-proliferative activity on M12 cell line
M12 cells were the most affected by the drugs. The majority of the compounds had IC50
values under 10 nM, which was the lowest concentration of drug tested. 26, a saturated analog in
the 7 membered ring series, had the most activity. (Figure 18) With many of the IC50 values
being lower than the lowest concentration tested, the standard error places the IC50 values of
these compounds very close to each other, making it difficult to analyze which structural features
are most important. For the M12 cell line, the therapeutic index (not calculated) of the
compounds will be more important to determine a new lead.

26 in M12

% inhibition of proliferation

130.00%

97.50%

65.00%

32.50%

0%
10 uM

1 uM

100 nM

10 nM

[26]

Figure 18 Percent inhibition of M12 cell line by 26 at four concentrations.
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4. Anti-proliferative activity of deconstructed analogs
The deconstructed analogs, 1b, 20b, and 20c, along with the isomeric mixtures of 1b and
1c were analyzed in each cell line after incubation at 24, 48, and 72 hours. Tables 3, 4, and 5
show the percent inhibition of each compound tested at 72 hours in the three cell lines. StructureActivity comparisons can be made directly between 20b and 20c to determine which sidechain is
more critical for activity. Comparing 1b and 20b can elucidate whether a cis double bond is more
favorable than a saturated bond. Care must be taken when using the data from either mixture to
draw any conclusions about structure-activity relationships. Because they are isomeric mixtures
the individual contribution to activity of each component cannot be measured. For series 2, the
cis isomer was tested individually so some insight can be gained by comparing it to the isomeric
mixture, which contains 80% trans isomer.
Compounds 20b and 20c are constitutional isomers; they both have one saturated
sidechain but the sidechain is in a different position on the imidazolinium core. In the PC-3 cell
lines, 20c had the highest activity of all compounds tested. 20b had significantly less activity. In
the M12 cell line, 20c again had relatively high activity and 20b relatively less activity. In these
two cell lines there is a clear difference in activity between sidechain positions. The relationship
is less clear in the DU-145 cell line, where both compounds have similar IC50 values. Looking at
a chart of their anti-proliferation activity shows an interesting activity profile. (Figure 19) At
higher concentrations, 20c has very high activity, but at lower concentrations this effect is greatly
reduced. At the lowest concentration, it has no effect at all. On the other hand, 20b does not
reach maximal effect but retains relatively high activity at lower concentrations of drug. The
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concentration where both produce a half maximal effect is nearly the same, but the overall effect
is different.

per cent inhibition of proliferation

20b and 20c in DU-145 at 72 hours
140.0%
110.0%
80.0%
50.0%
20.0%
-10.0%

DU-145 10 uM

1 uM

100 nM

10 nM

concentration of drug

20b

20c

Figure 19. The percent inhibition of both saturated deconstructed analogs in DU145 cell line.

Compounds 1b and 20b contain the same sidechain but differ only in the presence or
absence of a cis double bond. For the first 9 compounds, it seemed that the double bond did not
play much of a role in the overall activity of each molecule. Here is seems that in both the M12
and PC-3 cell line, the presence of a cis double bond significantly increases activity. In the
DU-145 cell line, there is a slight increase in activity of the saturated analog. The mixture of 1b
and its trans isomer maintained nearly the same activity as 1b alone in PC-3 and M12 cell lines,
maybe indicating that there is little difference between double bond configuration for this set of
compounds.
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Table 3. Percent inhibition of 1b, 20b, 20c, and isomeric mixtures 1b and 1c in the M12 cell line
at 72 hours.
M12
10 uM
1 uM
100 nM
10 nM
20c
111.72% ± 1.19% 113.82% ± 4.09% 90.38% ± 21.08% 59.04% ± 3.51%
1b
113.08% ± 3.35% 109.06% ± 6.67% 83.20% ± 14.75% 48.89% ± 15.54%
20b
94.31% ± 13.23% 77.66% ± 8.68% 53.84% ± 12.69% 35.45% ± 18.34%
Mix of 1b & 17b 110.29% ± 0.81% 101.72% ± 17.06% 84.07% ± 15.99% 56.15% ± 9.39%
Mix of 1c &17c 105.00% ± 6.38% 94.54% ± 2.72% 85.62% ± 9.30% 43.01% ± 11.21%

Table 4. Percent inhibition of 1b, 20b, 20c, and isomeric mixtures 1b and 1c in the PC-3 cell line
at 72 hours.
PC-3
10 uM
1 uM
100 nM
10 nM
20c
124.83% ± 7.82% 118.92% ± 7.75% 84.87% ± 9.55% 44.14% ± 16.90%
1b
125.77% ± 8.98% 102.26% ± 14.23% 94.44% ± 6.45% 36.26% ± 25.98%
20b
81.14% ± 1.92% 74.35% ± 2.46% 7.66% ± 1.13%
1.76% ± 2.19%
Mix of 1b & 17b 129.42% ± 9.69% 92.00% ± 9.09% 87.60% ± 16.02% 43.20% ± 25.47%
Mix of 1c &17c 123.75% ± 4.94% 91.53% ± 15.21% 89.03% ± 11.34% 30.38% ± 21.23%

Table 5. Percent inhibition of 1b, 20b, 20c, and isomeric mixtures 1b and 1c in the DU-145 cell
line at 72 hours.
DU145
10 uM
1 uM
100 nM
10 nM
20c
128.68% ± 8.46% 99.58% ± 4.08% 31.38% ± 4.60% -3.02% ± 4.04%
1b
126.60% ± 4.43% 51.33% ± 5.08% 11.35% ± 5.57% -11.26% ± 6.21%
20b
77.05% ± 6.12% 55.14% ± 9.44% 51.00% ± 1.58% 30.84% ± 3.27%
Mix of 1b & 17b 128.79% ± 4.13% 53.09% ± 7.60% 18.04% ± 5.59% 5.04% ± 7.70%
Mix of 1c &17c 125.68% ± 5.24% 54.20% ± 8.93% 8.59% ± 14.97% -6.39% ± 11.00%
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5. Anti-proliferative effect over time
Measuring the effect at earlier hours establishes a timeline for inhibitory activity. Because
of the large difference in control cells among each day, it is better to analyze the drug effect by
looking at the absorbance values rather than percent inhibition calculated values. By following a
concentration of drug through the time intervals and comparing them to the control values for
each time interval we can see how the drug effects the cell proliferation over a short period of
time. 20c will serve as a representative example to monitor how the drugs effect the cells. (Table
6)
In the DU-145 cell line, the control cells grew to near confluence by the end of the first
24 hours after drug incubation, the control absorbance values increased slightly over the next one
and two days. At the highest concentration of 20c, an anti-proliferative effect is seen immediately
and the cells do not recover growth. The absorbance values for 24, 48, and 72 hours remain
within standard error of each other. At 1 µM, the absorbance values are slightly less than the
control at 24 hours but by 72 hours, the absorbance has significantly decreased. At 100 nM, the
absorbance remain about the same over all three days, ultimately at 73% of the control value.
The cells incubated with the lowest concentration, 10 nM, grew slowly in the presence of drug,
at about the same rate as the control cells. At higher concentrations, the cell proliferation was
significantly inhibited and absorbance decreased over time.
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Table 6 Absorbance values of 20c at three time intervals in three cell lines.
drug/cell line

time

control cells

10 µM

1 µM

100 nM

10 nM

20c
DU145

24 hours

1.103 ± 0.028

0.523 ± 0.036

0.959 ± 0.027

1.060 ± 0.044

1.085 ± 0.029

48 hours

1.155 ± 0.007

0.597 ± 0.054

0.961 ± 0.088

1.104 ± 0.051

1.144 ± 0.018

72 hours

1.181 ± 0.025

0.547 ± 0.029

0.691 ± 0.007

1.027 ± 0.019

1.196 ± 0.030

24 hours

0.664 ± 0.045

0.536 ± 0.016

0.581 ± 0.030

0.591 ± 0.031

0.628 ± 0.033

48 hours

0.924 ± 0.054

0.562 ± 0.022

0.740 ± 0.086

0.824 ± 0.106

0.821 ± 0.032

72 hours

1.084 ± 0.022

0.556 ± 0.016

0.581 ± 0.011

0.724 ± 0.066

0.899 ± 0.071

24 hours

0.705 ± 0.010

0.579 ± 0.016

0.592 ± 0.015

0.678 ± 0.019

0.726 ± 0.017

48 hours

0.959 ± 0.010

0.673 ± 0.060

0.687 ± 0.065

0.773 ± 0.056

0.856 ± 0.042

72 hours

0.946 ± 0.070

0.547 ± 0.021

0.539 ± 0.035

0.615 ± 0.056

0.735 ± 0.040

20c
PC-3

20c
M12

In the PC-3 cell line, the pattern of inhibition was different than in DU-145 for the same
drug. The control cells proliferated steadily throughout the time interval. Again the highest
concentration of drug halted cell proliferation at all time intervals. The absorbance values for 1
µM remained constant for each day. At 100 nM in 24 hours the cells showed no proliferation but
had grown slightly by 72 hours, meaning that the compound is not toxic. The absorbance
increase daily with 10 nM of drug but the inhibition of proliferation was still greater than 50%
after 72 hours.
The proliferation of the M12 cell line was greatly inhibited by 20c. M12 control cells also
had the lowest absorbance values of all cell lines. For all concentrations of drugs, the 48 hour
absorbance values were the highest. At 24 hours, the drug absorbance values were much lower
than control, then increased slightly and ultimately the absorbance values fell even lower by 72
hours, except for 10 nM which had nearly the same absorbance values on days 1 and 3.
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There are many variables to account for the difference in activities of the compounds
among cell lines. First is expression of CCR5 which has already been discussed. Downstream
signaling pathways of the cells may compensate differently to the antagonism of CCR5 among
cell lines. The genetic material effected by the activity of the CCR5 is also influenced by other
signaling cascades. Other pathways and second messenger systems among cell lines can delay or
negate the effect of our drug. Finally, the rate of growth of the cells compared to concentration of
drug is different among cell lines. At plating, there are approximately 1000 cells in each well.
After one day of growth, drug is added so that the drug concentration of the well is fixed. As time
progresses, presuming the cells are still growing, there will be a lower concentration of drug
compared to the amount of cells in each well. Drug metabolism is another factor effecting its
concentration over time. Coupling that with the difference in receptor expression levels can
explain why there are not only differences among cell lines but among each day of growth.
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C. Molecular Dynamics Simulations and Docking of Anibamine and Its Analogs
Two homology models of chemokine receptor CCR5 were previously generated in our
lab.88 One was based on the crystal structure of !2 adrenergic receptor (PDB code 2RH1) with a
resolution of 2.4 Å and one was based on the crystal structure of bovine rhodopsin (PDB code
1F88) at 2.8 Å. The crystal structure of bovine rhodopsin contains a bound antagonist, retinal,
resulting in a model in the “dark state” while !2-AR was crystallized with an inverse agonist,
carazolol. No mutagenesis data is available for anibamine in the CCR5 receptor while data from
studies with other CCR5 ligands suggest Glu283 as a hydrogen bond acceptor to protonated
quaternary nitrogen atoms. Therefore this residue was used as a starting point for defining the
binding pocket of anibamine and its analogs.

1. Construction of anibamine and its analogs.
The docking conformation of anibamine has been previously studied in the two
homology models of CCR5.88 Molecular models of the anibamine and eight synthesized analogs
were developed in Sybyl. (Figure 20) The lowest energy conformation of each ligand was saved
for use in GOLD.

2. Dynamics simulation of prepared homology models for docking studies.
The prepared homology models were accessed with anibamine bound in the proposed
binding pocket. A dynamics simulation of anibamine docked into each receptor was performed in
an attempt to enlarge the binding pocket with defined aggregates and constraints. An averaged
structure was saved for ligand docking in GOLD.
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Figure 20. Structure of anibamine and docked ligands.

3. GOLD docking of ligands into CCR5 homology models.
Automated docking of all ligands was performed using GOLD3.1. Two constraints were used
to guide the ligands to the proposed binding pocket of the receptor. A distance constraint directed the
charged nitrogen atom of the ligand to the carboxylate group on Glu283. A similarity constraint based
on the common core (Figure 21) derived from the previously bound anibamine molecule was also
used to guide ligands to the proposed binding pocket. The number of operations in each GOLD run
was increased to 300,000 to accommodate the flexible sidechains. The top ranked configurations of

each ligand was visualized in Sybyl.
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Figure 21. The common indazolinium core of anibamine and all docked ligands with labeled key
carbons.
Comparisons of the binding modes of anibamine and other known CCR5 antagonists
were made using both models. Based on how the GOLDscore is produced, each of the
compounds with two sidechains ultimately resulted in higher GOLDscores than the
deconstructed analogs. Because they are larger, they inherently have more interactions to raise
the GOLDscore. All the ligands bound to the receptor in roughly the same binding pocket in both
models, therefore, the majority of the discussion focuses on the configurations of the ligands
themselves.

4. Analysis of ligand binding to CCR5 model based on 1F88 structure
Anibamine and eight analogs were docked into the CCR5 receptor model based on the
rhodopsin crystal structure using GOLD3.1. The GOLDscores for each ligand are presented in
table 7. The highest ranked ligands were anibamine (1a), its saturated analog (20a) and its
geometric isomer (17a). The trans analogs of all series (17a, 17b and 17c) had the lowest
scores.It seemed that the trans configuration at the double bond decreases the GOLDscore.
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Table 7. GOLDscores in 1F88 CCR5 model
ligand
Fitness
s(hb_ext) s(vdw_ext) S(hb_int)

s(int)

s(con)

Anibamine (1a)

73.06

0.00

61.67

0.00

-21.62

9.88

1b

58.67

0.00

43.29

0.00

-9.34

8.49

1c

58.19

0.00

41.58

0.00

-7.78

8.80

17a

61.71

0.00

56.31

0.00

-23.75

8.03

17b

54.09

0.00

39.78

0.00

-7.92

7.32

17c

54.41

0.00

38.92

0.00

-7.74

8.65

20a

65.96

0.00

62.08

0.00

-28.67

9.27

20b

59.84

0.00

42.02

0.00

-6.70

8.76

20c

57.54

0.00

40.81

0.00

-7.50

8.91

Note: Cmpd. – compound; S – Gold score component; hb – hydrogen bonding; vdw – Van der Waals
interactions; ext – external interactions; int – internal interactions. Con-constraint.

Figure 22. Binding of anibamine (in ball and stick) in the CCR5 model based on 1F88 (capped
sticks).
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When each top-ranked ligand was visualized in Sybyl, it became apparent that the core of
the ligand was flexible in the binding pocket. For the sake of clarity, the sidechain at C-8 will be
referred to as the ortho sidechain as it is positioned next to the 5-membered ring on the pyridine
ring; the sidechain at C-6 will be referred to as the para sidechain as it is across the pyridine ring
from the 5 membered ring. Interestingly, there was enough flexibility in the pocket surrounding
the core to allow for different ligands to position their sidechains differently such that not all para
sidechains fell in one direction while not all ortho sidechains bound in another direction. One
sidechain channel pointed down into the protein and the other sidechain binding pocket stretched
to the side of the protein. Helix 6 was in between each sidechain, lending some hydrophobic
properties to both with amino acids Tyr251, Phe245, and Trp248 depending on their sidechain
configuration. Because all compounds share the same binding pocket, the amino acid residues
will be described based on their relationship to anibamine in its current binding mode. (Figure
22) The nitrogen on the imidazolinium core is within ionic bonding distance of Glu283 on helix
7. Tyr108 and Phe182 are close enough to offer some pi-stacking interactions with the aromatic
core of the molecule. The para sidechain of anibamine points out towards the side of the protein
between helices 3 and 6. The long aliphatic sidechain is bordered by Val199, Phe182, and Ile198.
The ortho sidechain burrows into the protein, making possible hydrophobic interactions with
Phe117 on helix 1, Ile240, Val243, Tyr244, and Phe247 along helix 6. All other ligands docked in
the same pocket and interacted with the same (or fewer) amino acid residues.
When looking at the shape of the 5-membered ring in each bound ligand, a direct
correlation to the GOLDscore was noticed. The three lowest scoring compounds (17b, 17c, and
20c) and compound 17a, the lowest scored of the double-sidechain compounds all had C3 in the
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5-membered ring positioned towards Glu283/helix 7. In all other compounds, C3 pointed away
from helix 7. The double bond configuration may play a role in the conformation of the 5
membered ring. Ligand 20c is saturated but the angle of the bonds between carbons in the
docked conformation more closely resembles a trans bond. All the other ligands with this shape
have trans double bonds. The direction of the 5-membered ring might be playing a role in
lowering the GOLDscore.
There did not appear to be any amino acid residue in a position to favor any double bond
configuration. For each set of compounds the trans isomer ranked the lowest, but this may be
attributed to the conformation of the 5-membered ring. The higher scores of the saturated and cis
analogs compared to the trans analogs could also be a result of the simulations undertaken with
anibamine as the docked ligand.

Figure 23 Binding configuration of 20a (left) and anibamine (right) in the 1F88-based model.
The ligands with two sidechains bound the receptor in different ways. The anibamine
analog 20a, with 2 saturated sidechains, was bound in an inverted manner compared to
anibamine. When superimposed, the atoms of the 5-membered rings of the compounds
overlapped, but the nitrogens do not match up resulting in the para sidechain of one ligand
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sharing the same binding pocket with the ortho sidechain of the other. (Figure 23) Despite this
difference, these two compounds had the highest GOLDscores. The geometric isomer of
anibamine (17a) bound in a similar manner to anibamine but had a lower GOLDscore.

Figure 24. Overlay of Anibamine (green) and 1c (magenta) in 1F88-based model

Figure 25. Overlay of 20a (magenta) and 20c (yellow) in 1F88-based CCR5 model.
The position of the sidechain seemed to not have much effect on the rank of the
GOLDscores. All the compounds with only the ortho sidechain (1b, 17b, and 20b) as well as 1c
docked with their only sidechain directing to the side of the protein. The binding mode for ligand
1c directly overlaps with the top ranked binding mode for anibamine (Figure 24) although their
scores are very different. Compounds 17c and 20c were the only compounds with one sidechain
to bind in such a manner that their sidechains pointed into the protein. Their structures can be
overlapped with the of 20a, which is the only other compound to have the para sidechain in that
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binding channel. Figure 25 shows the overlap of 20a and 20c in the binding pocket of CCR5.
Though the scores for 1b, 1c, and 20b are higher than compounds 17c and 20c, ligand 17b has
the lowest GOLDscore. This may indicate that the shape of the 5-membered ring is more
important in the scoring process than where the sidechain is located. In the three highest ranked
compounds, a similar trend is observed. Anibamine and 20a, although their sidechains bind in a
manner opposite from the other, have higher GOLDscores than 17a which binds in the same way
as anibamine regarding the sidechains but has a different conformation in the 5-membered ring.
The more sensitive part of the molecule for binding may indeed be the indazolinium core rather
than the sidechains.

5. Analysis of ligand binding to CCR5 model based on 2RH1 structure
The same ligands were docked into the homology model based of the crystal structure of
!2-AR. The GOLDscores for each ligand are presented in table 8. With the exception of the score
for anibamine, the value of the GOLDscores obtained for this model were close to the scores
obtained for the homology model based on bovine rhodopsin. In this model, the saturated ligand
20a ranked higher than anibamine (1a). All the trans isomers (17a, 17b, and 17c) ranked lower
than their respective saturated analog (20a, 20b, and 20c). The cis ligand (1c) ranked highest in
series c. Ligand 20b ranked highest in the b series.
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Table 8. GOLDscores of ligands docked into the 2RH1-based CCR5 model
ligand
Fitness
s(hb_ext) s(vdw_ext) S(hb_int)
s(int)

s(con)

Anibamine (1a)

61.15

0.00

53.62

0.00

-20.33

7.76

1b

52.75

0.00

39.24

0.00

-9.92

8.72

1c

53.94

0.00

39.02

0.00

-12.29

8.24

17a

55.82

0.00

52.19

0.00

-23.64

7.70

17b

53.86

0.00

41.25

0.00

-10.21

7.35

17c

52.57

0.00

39.43

0.00

-10.64

9.00

20a

63.30

0.00

60.54

0.00

-28.80

8.72

20b

55.46

0.00

40.44

0.00

-8.34

8.20

20c

53.10

0.00

53.06

0.00

-8.56

8.28

Note: S:Gold score component; hb:hydrogen bonding; vdw:Van der Waals interactions; ext:external
interactions; int:internal interactions. Con:constraint.

In contrast to the binding modes adopted in the rhodopsin-based model, one sidechain
from each compound docked into the same pocket in the !2-AR based model. There was less
overlap of the common cores of the molecule when compared to the previous docking study. The
ligands with two sidechains displayed varied placement of the second sidechain. The binding
modes of anibamine (1a) and 20a are depicted in figure 26. The residues highlighted in the figure
are residues found in the previously published docking study that participated in binding of
anibamine. They also play a role in the binding of 20a. The higher score of 20a may be due to
the closer proximity of one sidechain to Phe109, Tyr190, and Phe264. The second sidechain of
each ligand points out toward the extracellular space. The second sidechain of ligand 17a also
pointed toward the extracellular space. The ligands with one sidechain adopted conformations
that placed the sidechain in the vicinity of Phe109, Tyr190, and Phe 264 as well.
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Figure 26. Binding of 1a (left, ball and stick) and 20a (right, ball and stick) in !2-AR based
model (capped sticks).
To adopt a conformation to place the sidechain in the pocket bordered by hydrophobic
residues, the imidazolinium cores of the ligands adopted various conformations and there was no
overlap. The binding modes of all series c ligands are shown in Figure 27. The sidechain of each
ligand occupies roughly the same space in the receptor model, but it is clear that the cores are in
different orientations. All ligands were within ionic bonding distance of Glu283. The
GOLDscores did not seem to be effected by the shape of the core like they were in the rhodopsin
based model.

Figure 27. The binding modes of 17c (left), 20c (center) and 1c (right) in !2-AR based model.
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6. Comparison of ligand docking in each receptor
Newly synthesized ligands were docked into previously constructed CCR5 homology
models. The GOLDscores for ligands with two sidechains were higher in comparison to other
ligands in both models. Despite using a similarity constraint for docking using the core common
to all ligands, the binding modes of the pyridinium core varied in the same binding pocket. For
both receptors, it seemed the interactions between the sidechains of the ligands with the amino
acid residues of the receptor were more important than the position of the core. More overlap of
cores among ligands was observed in the 1F88 based model. In the !2 adrenergic receptor based
model, one sidechain from each ligand docked into the same side of the binding pocket. Though
the distribution of the sidechain binding mode in this receptor was more widely shared between
ligands, almost no core overlap was observed. Both models present intriguing insights into the
binding mode of the receptor, especially in regard to deconstruction. Because there was no
defined place for the para or ortho sidechains to bind consistently in each model, it invites the
question of whether the two series of deconstructed analogs might not be that different.
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V. Conclusions

The high rate of prostate cancer metastasis related mortality coupled with the increase in
the population of men over 50 years of age necessitates the development of novel therapeutics
for the treatment of prostate cancer. Through the investigation of the inflammatory network in
prostate cancer, the chemokine receptor CCR5 was found to be overexpressed in metastatic
prostate cancer cell lines.6 This was followed by the discovery that a CCR5 antagonist inhibited
proliferation of PCa cell lines.7 A novel natural product, anibamine, was isolated and found to be
a micromolar inhibitor of the receptor.10,11 Anibamine was used as a new anti-prostate cancer
lead compound. The total synthesis of anibamine was completed from acetyl acetone in either ten
or eleven steps. To discover the pharmacophore, analogs of anibamine were designed using the
“deconstruction-reconstruction-elaboration” approach. The goal of this project to synthesize
deconstructed analogs of anibamine each with a trans analog and a saturated analog. The
establishment of a stereoselective route to only one isomer was desired as well, to increase yield
and eliminate elaborate purification procedures.
Anibamine and eight analogs were successfully prepared by following the total synthesis
of anibamine. Six new deconstructed analogs were synthesized from intermediates 2a and 2b
then paralleling the synthetic route of anibamine. Separation of the isomers proved very difficult.
Ultimately separation of penultimate intermediates on prep TLC was deemed the best way to
separate the cis and trans isomers. Stereoselective synthesis would remove the need to separate
isomers. Five different reaction conditions repeated among different aldehyde substrates were
explored, resulting in cis:trans ratios as high as 1:1. Solubility of the long aliphatic chain
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reagents appeared to be the main hindrance in successful stereoselective synthesis. Other
synthetic routes are being explored to improve stereoselectivity in the hopes of making separation of
isomers a non issue.
From the anti-proliferative data, however, the double bond configuration had less of an
influence on activity. The compounds were tested in four different concentrations at an incubation
time of 72 hours. In the DU-145 cell line, the 5-membered ring compounds had the highest activity.
The 7-membered rings were the most potent in the PC-3 cell line. The majority of compounds had
very strong anti-proliferative effect in the M-12 cell line, making it hard to distinguish a clear
structure-activity relationship. Each cell line has a different expression level of CCR5 which can
account for some of the differences in activity. Differences in signaling cascades and compensation
mechanisms can also play a role in the different cell lines. The deconstructed analogs were also
tested at 24 and 48 hours incubation times to both further validate the use of the 72 hours incubation
time and to examine the effect of the drugs over a three day time interval. The drugs effected the cell
lines at different rates but by 72 hours the overall effect of each drug had stabilized. Of the
deconstructed analogs, the para sidechain drug, 20c had the highest activity in each cell line,
indicating that this sidechain may be more important for activity.
In the modeling studies, two different homology models of CCR5 were used to observe the
possible binding mode of the synthesized ligands. The shared core of anibamine was used as a
similarity constraint to direct the ligands to the proposed binding pocket. Interestingly, the ligands
with only one sidechain frequently flipped the imidazolinium core so that the sidechain directed into
the same area of the binding pocket in both models. Even the ligands with two sidechains
interchanged what side of the binding pocket each sidechain occupied. Without defined binding
pockets for each sidechain, the deconstructed analogs can bind in a way nearly identical to its
geometric isomer, leaving little difference between analogs.
These studies are the beginning of a thorough exploration into the structure-activity
relationship of anibamine. These data combined with future results will identify a next generation
lead compound for anti-prostate cancer activity.
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VI. Experimental
1. Chemical Synthesis
Melting points were determined on a Fisher-Scientific melting point apparatus. 1H-NMR and

13C-

NMR spectra were obtained on a Varian Gemini 300 MHz spectrometer, Varian Mercury 300MHz
NMR spectrometer or Brucker 400 MHz spectrometer and tetramethylsilane was used as an internal
standard. Infrared spectra were obtained on a Nicolet 5ZDX FT-IR spectrometer. Column
chromatography was performed on silica gel (grade 60 mesh; Bodman Industries, Aston, PA).
Routine thin-layer chromatography (TLC) was performed on silica gel GHIF plates (250 µm, 2.5 x
10 cm; Analtech Inc., Newark, DE). Preparative TLC was performed on Partisil PK6F plates (250
µm and 500 µm, 20 x 20 cm; Whatman Int. Ltd. Maidstone, England). Preparative HPLC was
performed on a Varian Dynamax Microsorb 100-5 CN column (250 x 21.5mm), using Prostar 325
UV-Vis (254, 280nm) as the detector.

A. Intermediates in synthesis of Series a:
Route 1:
3-((Dimethylamino)methylene)pentate-2,4-dione (3)

A neat mixture of N,N-dimethylformamide dimethyl acetal (18.77 g, 157.7 mmol) and
acetylacetone (7.76 g, 77.6 mmol) was refluxed for 2 hours. The mixture was then concentrated
to remove excess acetal to give a dark red oil. The crude product was recrystallized in EtOAc to
give 3-((dimethylamino)methylene)pentate-2,4-dione (8.562 g, 71% yield) as light yellow
crystals. M.p. 55-57! 1HNMR (300 MHz, CDCl3) & 7.45 (s, 1H), 3.00 (s, 6 H), 2.34 (s, 6H).
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1-(5-Methylisoxazol-4-yl)ethanone (4)

A solution of 3-((dimethylamino)methylene)pentate-2,4-dione (4.662g, 30 mmol) and
hydroxylamine hydrochloride (2.885g, 30 mmol) in 50 mL MeOH was refluxed for 2 hours. The
mixture was concentrated to remove MeOH then partitioned between 50 mL water and 100 mL
dichloromethane. The CH2Cl2 layer was dried over Na2SO4, filtered and concentrated. The
residue was purified by reduced pressure distillation to give 1-(5-methylisoxazol-4-yl)ethanone
(1.922 g, 51% yield) as a colorless oil. 1HNMR (300 MHz, CDCl3) & 8.49 (s, 1H), 2.73 (s, 3 H),
2.47 (s, 3H).

(E)-2-Methyl-4-oxo-3-(phenylamino)pent-2-enenitrile (5)

A mixture of aniline (1.295g, 13.8 mmol) and 1-(5-methylisoxazol-4-yl)ethanone (580 mg, 4.6
mmol) was refluxed for 15 minutes. After cooling the mixture was poured into ice cold 2M HCl
and stirred while a precipitate formed. The precipitate was recrystallized in EtOH to give (E)-2methyl-4-oxo-3-(phenylamino)pent-2-enenitrile (504 mg, 54% yield) as clear plate crystals.
M.p.: 132-133! 1HNMR (300 MHz, CDCl3) & 7.47-7.35 (m, 3H), 7.14 (m, 2H), 2.43 (s, 3H),
2.27 (s, 3H).
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Route 2:
2-hydroxy-4,6-dimethylnicotinonitrile (2b)

Cyanoacetamide (0.84 g, 10 mmol) was dissolved in a solution of K2CO3 (0.40 g, 2.89 mmol) in
water (20 mL). Then acetylacetone (1.00 g, 10 mmol) was added and the reaction stirred
overnight at room temperature. The precipitate was filtered and washed with hexane to give 2hydroxy-4,6-dimethylnicotinonitrile (1.35 g, 91% yield) as a white powder. M.p.: 118-119!
1HNMR

(300 MHz, CDCl3) & 12.38 (br, 1H), 6.15 (s, 1H), 2.28 (s, 3H), 2.21 (s, 3H).

5-bromo-2-hydroxy-4,6-dimethylnicotinonitrile (6)

2-Hydroxy-4,6-dimethylnicotinonitrile (148 mg, 1 mmol) was dissolved in trifluoroacetic acid
(0.3 mL) at 0˚C. H2SO4 (0.4 mL) was added followed by NBS (356 mg, 2 mmol). The reaction
was kept at 0! for 1.5 hours then poured into crushed ice. The resulting precipitate was filtered
and recrystallized in a 4:1 mixture of acetone and water yielding 5-bromo-2-hydroxy-4,6dimethylnicotinonitrile (161 mg, 71% yield) as white crystals. M.p.: 256-257! 1HNMR (300
MHz, CDCl3) & 12.84 (br, 1H), 2.43 (s, 3H), 2.37 (s, 3H).
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2-hydroxy-4,6-dimethylpyridine-3,5-dicarbonitrile (2a)

Route 1: A solution of (E)-2-methyl-4-oxo-3-(phenylamino)pent-2-enenitrile (500 mg, 2.5
mmol), malononitrile (165 mg, 2.5 mmol), and KOH (140 mg, 2.5 mmol) in 20 mL MeOH was
refluxed overnight while a precipitate formed. The precipitate was filtered and dried to give 2hydroxy-4,6-dimethylpyridine-3,5-dicarbonitrile (320 mg, 74% yield) as a white powder. Route
2 (Rosemund von Braun Reaction): CuCN (819 mg, 9.1 mmol) was dissolved in DMF (4 mL).
5-bromo-2-hydroxy-4,6-dimethylnicotinonitrile (730 mg, 7.6mmol)was added slowly then more
DMF (2 mL) was added. The reaction was refluxed under N2 protection for 50 hours. The room
temperature reaction mixture was poured into an FeCl3 solution (4 g FeCl3, 4 mL H2O, 1 mL
HCl) and stirred at 60! for 20 minutes. Then ice was added to 50 mL total volume. The water
solution was extracted with 75 mL EtOAc three times. The combined organic layers were
washed with brine, dried over Na2SO4, filtered and concentrated to give 200 mg crude product.
The water layer was neutralized with 1M NaOH until filtration of inorganic salt was needed. The
water layer was again extracted with EtOAc three times. The combined organic layers were
washed with brine, dried over Na2SO4, filtered and concentrated to give 250 mg crude product.
The inorganic salts were washed with EtOAC multiple times, the EtOAc was decanted off the
brown aqueous mixture. The combined organic layers were dried over Na2SO4, filtered and
concentrated to give 300 mg crude product. The crude products were recrystallized in AcOH to
give 2-hydroxy-4,6-dimethylpyridine-3,5-dicarbonitrile (671 mg, 51% yield) as a white powder.
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Route 2 (Domino Halide reaction): NaCN (47 mg, 0.96 mmol), CuI (15 mg, 0.08 mmol), KI
(27 mg, 0.16 mmol), and 5-bromo-2-hydroxy-4,6-dimethylnicotinonitrile were added to a three
neck flask equipped with a condenser. The flask was evacuated and filled with N2 three times
before addition of anhydrous toluene (1 mL) and N,N-dimethylethylenediamine (85 µl, 0.8
mmol). The reaction was heated to reflux and stirred for 24 hours. An additional 20 mL of
toluene was added over the course of the reaction to dissolve more 5-bromo-2-hydroxy-4,6dimethylnicotinonitrile. After 24 hours, TLC showed some product but mostly starting material.
The reaction was stopped and the product was not isolated. M.p.: decomposed at 260! 1HNMR
(300 MHz, DMSO) & 3.33 (br, 1H), 2.49 (s, 3H), 2.22 (s, 3H).

After convergence of Routes 1 and 2:
2-Bromo-4,6-dimethylpyridine-3,5-dicarbonitrile (8a)

A solution of 2-hydroxy-4,6-dimethylpyridine-3,5-dicarbonitrile (420 mg, 2.4 mmol), TBAB
(933 mg, 2.9 mmol) and P2O5 (1.45 g, 10 mmol) was heated in toluene (60 mL) under N2
protection for 4.5 hours. Ice was added to the reaction mixture, the toluene layer was separated
and kept. The water layer was neutralized with NaHCO3. The water layer was then extracted
with EtOAc (50 mL) three times. The combined organic layers were washed with brine, dried
over Na2SO4, filtered and concentrated to give 1.08 g crude brown solid. The crude product was
purified by column chromatography on Al2O3 with a Hexane:EtOAc solvent system (20:1 v/v) as
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eluent to give 2-bromo-4,6-dimethylpyridine-3,5-dicarbonitrile (430 mg, 75% yield) as a white
powder. M.p.: 127-129! 1HNMR (300 MHz, CDCl3) & 2.83 (s, 3H), 2.78 (s, 3H).

1-Methoxy-4-((prop-2-ynyloxy)methyl)benzene (10)

A solution of 4-methoxybenzylalcohol (1.66g, 12 mmol) in anhydrous Et2O (12 mL) was added
to a suspension of g NaH (29 m, 1.2 mmol) at room temperature and stirred for 30 minutes under
N2 protection before cooling to 0!. Trichloroacetonitrile (1.73 g, 12 mmol) was added, and the
reaction mixture was allowed to warm up slowly to room temperature over 4 hours. The solvent
was evaporated, the residue was dissolved in dry hexane (14 mL) and dry MeOH (0.06 mL) and
filtered through celite then concentrated to give a yellow oil (1.9 g). The crude imidate was
dissolved in hexane and dichloromethane (30 mL, 2:1 v/v). Propargyl alcohol (448 mg, 0.8
mmol) was added to the reaction and the solution was cooled to 0! and treated with a catalytic
amount of 10-camphorsulfonic acid. The reaction was stirred for 20 hours under N2 protection
while a white precipitate formed. The solution was filtered through celite, washed with saturated
aqueous sodium bicarbonate, dried over sodium sulfate, filtered and concentrated to give 1.4 g
crude product. The crude product was purified on silica gel with hexane:EtOAc (25:1 v/v) to
give 1-methoxy-4-((prop-2-ynyloxy)methyl)benzene (0.9 g, 64% yield)as a colorless oil.
1HNMR

(300 MHz, CDCl3) & 7.29 (m, 2H), 6.89 (m, 2H), 4.54 (s, 2H), 4.14 (d, J=2.4 Hz, 2H),

3.81 (s, 3H), 2.46 (t, J=2.4 Hz, 1H).
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2-(3-((4-Methoxybenzyloxy)prop-1-ynyl)-4,6-dimethylpyridine-3,5-dicarbonitrile (11a)

To a stirred suspension of 2-bromo-4,6-dimethylpyridine-3,5-dicarbonitrile (620 mg, 2.6 mmol),
CuI, (24 mg, 0.26 mmol), PdCl2(PPh3)2 (91 mg, 0.13 mmol), and triethylamine (18 mL) in
diethyl ether (60 mL) was added 1-methoxy-4-((prop-2-ynyloxy)methyl)benzene (554 mg, 3.15
mmol) in diethyl ether (2 mL) dropwise under N2 protection. The reaction was allowed to stir
under N2 protection for 6 hours while a precipitate formed. Then water (25 mL) was added. The
organic layer was separated and the precipitate was filtered and recrystallized in EtOAc to yield
2-(3-((4-Methoxybenzyloxy)prop-1-ynyl)-4,6-dimethylpyridine-3,5-dicarbonitrile (565 mg, 66%
yield) as white crystals. M.p.: 130-131! 1HNMR (300 MHz, CDCl3) & 7.35 (m, 2H), 6.90 (m,
2H), 4.68 (s, 2H), 4.48 (s, 2H), 3.8 (s, 3H), 2.83 (s, 3H), 2.77 (s, 3H).

2-(3-((4-Methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5-dicarbonitrile (12a):

Hydrogenation was conducted on a mixture of 2-(3-((4-methoxybenzyloxy)prop-1-ynyl)-4,6dimethylpyridine-3,5-dicarbonitrile (475 mg, 1.42mmol) and Pd/C (47 mg, 10% by weight) in
MeOH (30 mL) under 50 psi H2 for 6 hours. The mixture was filtered through celite to remove
Pd/C and concentrated to remove MeOH to give 2-(3-((4-methoxybenzyloxy)propyl)-4,6dimethylpyridine-3,5-dicarbonitrile (450 mg, 95% yield) as a white solid without further
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purification. M.p.: 90-92! 1HNMR (300 MHz, CDCl3) & 7.19 (m, 2H), 6.84 m, 2H), 4.38 (s,
2H), 3.80 (s, 3H), 3.55 (t, J=6.0 Hz, 2H), 3.12 (m, 2H), 2.76 (s, 3H), 2.64 (s, 3H), 2.11 (m, 2H).

2-(3-((4-Methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5-dicarbaldehyde (13a)

Under N 2 protection, 2-(3-((4-methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5dicarbonitrile (90 mg, 0.26 mmol) was dissolved in anhydrous toluene (8 mL) then cooled to
-70!. After cooling, DIBAL-H (0.56 mL of 1.0 M solution of in toluene, 0.56 mmol) was added
dropwise over 15 minutes and stirred at -70! for 2 hours. After two hours, 1 additional
equivalent (0.26 mL of 1.0 M solution in toluene, 0.26 mmol) of DIBAL-H was added over 10
minutes and the reaction kept at -70!. Over the next 2.5 hours the reaction was allowed to
warm to 0!. Then 1.0 M H2SO4 (3.0 mL) was added and the resulting solution was stirred
overnight. The organic layer was separated; the aqueous layer was extracted with 10 mL EtOAc
three times. The combined organic layers were washed with saturated aqueous NaHCO3, brine,
and dried over Na2SO4, filtered and concentrated to give 130 mg crude product as a yellow oil.
The crude residue was purified by column chromatography on silica gel with a Hexane/EtOAc
solvent system (5:1 v:v) to give 2-(3-((4-Methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5dicarbaldehyde (68 mg, 74% yield) as a colorless oil. 1HNMR (300 MHz, CDCl3) & 10.61 (s,
1H), 10.59 (s, 1H), 7.24 (m, 2H), 6.87 (m, 2H), 4.41 (s, 2H), 3.80 (s, 3H), 3.51 (t, J=6.0 Hz, 2H),
3.15 (m, 2H), 2.77 (s, 3H), 2.75 (s, 3H), 2.05 (m, 2H).
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Non-1-yl triphenylphosphonium bromide (14)

1-Bromononane (1.035g, 5 mmol) and triphenylphosphine (1.310 g, 5 mmol) were refluxed in
toluene for 55 hours. After cooling, the toluene was removed by roto evaporation. The residue
was washed with diethyl ether and thoroughly dried yielding non-1-yl triphenylphosphonium
bromide in quantitative yield. 1H NMR (DMSO, 400 mHz) % 7.88-7.77(m, 15H), 3.56 (m, 2H),
1.47 (m, 4H), 1.19 (m, 10H), 0.82 (m, 3H).

2-(3-(4-Methoxybenzyloxy)propyl)-4,6-dimethyl-3,5-di((Z)-dec-1-enyl)pyridine and its three
isomers: (15a and isomers)

Traditional Wittig Reaction: Under N2 protection, non-1-yl triphenylphosphonium bromide
(1.100 g, 2.35 mmol) in toluene (6 mL) and LHMDS (2.1 mL of a 1.0 M solution of in THF, 2.1
mmol) were dissolved producing a bright red color. The solution was cooled to -70! then 2-(3((4-methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5-dicarbaldehyde (200 mg, 0.58 mmol)
in toluene (5 mL) was added dropwise over 15 minutes. The reaction was stirred at -70! for 15
minutes then warmed to room temperature. After stirring for 45 minutes at room temperature, the
reaction was quenched with saturated aqueous NH4Cl (18 mL) producing a colorless solution.
The organic layer was separated, the aqueous layer was extracted with EtOAc (50 mL) three
times. The combined organic layers were washed with brine, dried over Na2SO4, filtered and
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concentrated to give a crude oil (1.4 g). The crude product was purified by column
chromatography on silica gel with hexane:EtOAc (15:1 v/v) as eluent to give 2-(3-(4methoxybenzyloxy)propyl)-4,6-dimethyl-3,5-di((Z)-dec-1-enyl)pyridine and its three isomers
(240 mg, 73% yield) as a colorless oil. 1HNMR indicated 1:3 E:Z ratio. Schlosser Modification
to the Wittig Reaction: Under N2 protection, non-1-yl triphenylphosphonium bromide (164 mg,
0.35 mmol) and LiBr (61 mg 0.7 mmol) in anhydrous toluene/THF (5 mL, 4:1 v/v)) and PhLi
(0.2 mL of a 1.8 M solution in diisopropyl ether, 0.35 mmol) were dissolved producing a dark
orange solution. The resulting solution was cooled to -70!. The crude aldehyde 2-(3-((4Methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5-dicarbaldehyde (20 mg, 0.06 mmol) was
dissolved in toluene (1 mL) and added dropwise to the solution resulting in light orange solution.
After 20 minutes, PhLi (0.2 mL of a 1.8 M solution in diisopropyl ether, 0.35 mmol) was added
returning the reaction to a dark orange solution. After 20 minutes stirring at -70!, the reaction
was warmed to -25! and 1 M ethereal HCl (0.75 mL, 1 M solution in diethyl ether, 0.75 mmol).
After a few minutes, t-BuOK (100 mg, 0.9 mmol dissolved in a minimum amount of THF) was
added to the reaction. The reaction was allowed to warm to room temperature and stirred
overnight. Then water (5 mL) was added. The organic layer was separated. The aqueous layer
was extracted with EtOAc (20 mL) three times. The combined organic layers were washed with
saturated aqueous NaHCO3, brine, and dried over Na2SO4, filtered and concentrated. The crude
product was purified by column chromatography on silica gel with hexane:EtOAc (8:1 v/v) as
eluent to give 2-(3-(4-methoxybenzyloxy)propyl)-4,6-dimethyl-3,5-di((Z)-dec-1-enyl)pyridine
and its three isomers (20 mg, 50% yield) as a colorless oil. 1HNMR indicated 1:1 E:Z ratio.
Grignard Reaction: Pieces of Mg ribbon and a small amount of iodine were put in a 2 neck
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flask with a condenser and degassed and filled with N2 three times. Anhydrous THF (1 mL) was
added. 1-Bromononane (0.89 mL, 4.68 mmol) was added slowly, the reaction was heated with a
hot gun, then with an oil bath to maintain a slight reflux for two hours. After two hours the
reaction mixture looked clear and there was no visible Mg. It was cooled to 0! and 2-(3-((4methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3,5-dicarbaldehyde (60 mg, 0.18 mmol) in
THF (0.3 mL) was added dropwise. The reaction mixture was stirred 3 hours at 0!. TLC
monitoring showed no product had formed. In the morning, reaction was quenched with 10 mL
NH4Cl then the layers were disposed. The starting material was not recovered. 1HNMR (400
MHz, CDCl3) & 7.26(d, J=8.4 Hz, 2 H), 6.87(d, J=8.4 Hz, 2 H), 6.27(m, 2H), 5.78(m, 2H),
4.44(s, 2H),3.80(s, 3H), 3.50(m, 2H), 2.82(m, 2H),2.39(s, 3H), 2.22(m, 2H), 2.05(s, 3H), 1.93(m,
4H), 1.78 (m, 4 H), 1.28 (m, 20H),0.87 (m, 6 H).

3-(4,6-Dimethyl-3,5-di-((Z)-dec-1-enyl)pyridin-2-yl)propan-1-ol (16a) and its three isomers:

A mixture of 2-(3-(4-methoxybenzyloxy)propyl)-4,6-dimethyl-3,5-di((Z)-dec-1-enyl)pyridine
and its three isomers (70 mg, 0.12 mmol) was refluxed in EtOH (3 mL) and 1N HCl (1.5 mL) for
5 hours. After cooling, the solution was concentrated to remove EtOH. The aqueous layer was
extracted with CH2Cl2 (15 mL) three times. The combined organic layers were washed with
brine, dried over Na2SO4, filtered and concentrated. The crude product (56 mg) was purified by
column chromatography on silica gel with CH2Cl2:MeOH (40:1, v/v) as eluent to give 3-(4,6-
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dimethyl-3,5-di-((Z)-dec-1-enyl)pyridin-2-yl)propan-1-ol (13) and its three isomers (45 mg, 87%
yield) as a colorless oil. 1HNMR (400 MHz, CDCl3) % 6.25 (m, 2H), 5.82 (m, 1H), 5.66 (m, 1H),
3.72 (m, 2H), 3.00 (m, 2H,), 2.92 (br, 1H), 2.39 (s, 3H), 2.23 (m, 2H), 2.06 (s, 3H), 1.92 (m, 4H),
1.76(m, 4H), 1.48 (m, 4H), 1.28 (m, 16H), 0.89 (m, 6H).

B. Final products in Series a:
Anibamine and its three isomers

To a mixture of 3-(4,6-dimethyl-3,5-di-((Z)-dec-1-enyl)pyridin-2-yl)propan-1-ol (13) and its
three isomers (110 mg, 0.25 mmol) and triethyl amine (75 mg, 0.75 mmol) in CH2Cl2 (5 mL) at
0! was added MsCl (57 mg, 0.50 mmol) in CH2Cl2 (2 mL). The mixture was allowed to warm
to room temperature over 60 minutes, diluted with CH2Cl2 (25 mL), washed with brine, dried
over Na2SO4, filtered and concentrated. The crude product were separatedwas purified by
column chromatography on silica gel with CH2Cl2:MeOH (15:1, v/v) as eluent to give anibamine
and its three isomers (95 mg, 82% yield) as a colorless oil. The 95 mg of isomers was purified by
HPLC on a Varian Dynamax Microsorb 100-5 CN column (250 x 21.5mm) eluting with a 90 min
gradient CH3CN (47.5~52.5%)/H2O (0.1% TFA) at a flow rate of 8 mL/min. (47.5% H2O/52.5%
MeCN v/v + 0.1% TFA ).
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Anibamine: Fractions at 55-61 minutes were collected and combined to give 50 mg crude
product, which was purified by column chromatography on silica gel with CH2Cl2:MeOH (15:1,
v/v) as eluent to give 12 mg colorless oil.
E,E isomer (17b): Fractions at 77-84 minutes were collected and combined to give 40 mg crude
product, which was purified by column chromatography on silica gel with CH2Cl2:MeOH (15:1,
v/v) as eluent to give 14 mg colorless oil.
Anibamine isomers 19 and 20: Fractions at 55-61 minutes were collected and combined to give
70 mg crude product, which was purified by column chromatography on silica gel with
CH2Cl2:MeOH (15:1, v/v) as eluent to give 20 mg colorless oil. 1a 1HNMR (400 MHz, CD3CN)
% 6.30 (d, J= 11.4 Hz, 2H), 6.09 (d t, J= 11.4, 7.5Hz, 1H), 6.05(d t, J= 11.4, 7.5 Hz,1H), 4.65 (t,
J= 7.5Hz, 2H), 3.25 (m, 2H), 2.56 (s, 3H), 2.41 (m, 2H), 2.29 (s, 3H), 1.83 (m, 4H), 1.37 (m,
4H), 1.24 (m, 20H, 10 methylene groups), 0.89 (t, J= 6.9Hz, 6H);

13C

NMR (400 MHz,

CD3CN): % 154.8, 154.5, 148.1, 138.7, 138.6, 135.1, 131.5, 122.4, 121.4, 57.9, 32.3, 31.8, 31.8,
29.34, 29.31, 29.31, 29.24, 29.24, 29.24, 28.98, 28.77, 28.64, 28.51, 22.6, 22.6, 20.5, 18.4, 17.5,
13.6, 13.6. 17a 1HNMR (400 MHz, CD3CN) % 6 6.40 (d, J= 16.2 Hz, 1H), 6.34 (d, J= 16.5 Hz,
1H), 6.03 (d t, J= 16.2,6.9Hz, 1H), 5.83 (d t, J= 16.5, 6.9Hz, 1H), 4.62 (t, J= 7.5Hz, 2H), 3.41 (t,
J= 7.8Hz, 2H), 3.11 (m, 2H), 2.62 (s, 3H), 2.41 (s, 3H), 2.32 (m, 4H), 1.54 (m, 4H), 1.32 (m, 20
H), 0.91 (t, J=6.9Hz, 6H); 13C NMR (75MHz, CD3CN): % 153.6, 153.6, 147.7, 141.8, 141.6,
136.7, 132.3, 123.0, 122.4, 58.0, 33.2, 33.0, 32.8, 31.90, 31.87, 35.29, 35.29, 29.27, 29.27, 29.16,
29.07, 28.76, 28.71, 22.65, 22.65, 20.75, 18.57, 18.02, 13.66, 13.66.
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6,8-Didecyl-5,7-dimethyl-2,3-dihydro-1H-indolizinium (20a):

Hydrogenation was conducted on a mixture of 19a and 18a anibamine isomers (15 mg, 0.027
mmol) and Pd/C (2 mg, 10% by weight) in MeOH (2 mL) under 50 psi H2 for 6 hours. The
mixture was filtered through celite to remove Pd/C and concentrated to remove MeOH to give
6,8-didecyl-5,7-dimethyl-2,3-dihydro-1H-indolizinium (10 mg, 66% yield). 1HNMR: (400 MHz,
CD3CN) & 4.57 (m, 2H), 2.75 (m, 2H), 2.72 (m, 2H), 2,58 (s, 3H), 2.40 (s, 3H), 2.35 (m, 4H),
1.44 (m, 6H), 1.28 (m, 26 H), 0.89 (m, 6H)

13CNMR:

(400 MHz, CD3CN) % 153.81, 153.13,

146.97, 138.13, 134.76, 116.99, 57.42, 48.59, 45.53, 31.33, 29.26, 28.97, 28,94, 28.94, 28.74,
28.74, 28.68, 28.68, 28.64, 28.63, 28.07, 28.07, 27.85, 27.83, 22.09, 19.61, 16.12, 15.53, 13.08,
13.08.

C. Intermediates in synthesis of series b:
2-Bromo-4,6-dimethylnicotinonitrile (8b):

A solution of 2-hydroxy-4,6-dimethylnicotinonitrile (2.96 g, 20 mmol), TBAB (7.74 g, 24
mmol), and P2O5 (6.81 g, 48 mmol) in toluene (120 mL) was stirred at 90˚C for 24 hours. Then
ice was added to the hot reaction mixture. The organic layer was separated and the water layer
was extracted with EtOAc (50 mL) twice. The combined organic layers were washed with
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NaHCO3 and brine, dried over Na2SO4, filtered and concentrated to give 3.9 g crude product.
The crude product was recrystallized in EtOAc to yield 2-bromo-4,6-dimethylnicotinonitrile (3.6
g, 75% yield) as colorless needles. M.p.: 118-120!. IR (KBr, cm-1) &max: 3049, 2225, 1589.
1HNMR:

(300 MHz, CDCl3) & 7.12 (s, 1H), 2.60 (s, 3H), 2.57 (s, 3H).

13CNMR:

(300 MHz,

CDCl3) & 157.46, 148.70, 137.87, 118.08, 109.91, 106.15, 19.04, 15.28.

2-(3-((4-Methoxybenzyloxy)prop-1-ynyl)-4,6-dimethylnicotinonitrile (11b):

To a stirred suspension of 2-bromo-4,6-dimethylnicotinonitrile (422 mg, 2 mmol), CuI (38 mg,
0.2 mmol), PdCl2(PPh3)2 (70 mg, 0.1 mmol), and triethylamine (12 mL) in diethyl ether (50 mL)
under N2 protection was added 1-methoxy-4-((prop-2-ynyloxy)methyl)benzene in diethyl ether
(5 mL) dropwise. The reaction was allowed to stir for 40 hours. Then water (25 mL) was added.
The organic layer was separated, the water layer was extracted with EtOAc (50 mL) twice. The
combined organic layers were washed with brine and dried over Na2SO4, filtered and
concentrated. The crude residue was recrystallized in EtOAc to yield 2-(3-((4methoxybenzyloxy)prop-1-ynyl)-4,6-dimethylnicotinonitrile (485 mg, 79% yield) as colorless
needles. M.p.: 80-82!. IR (KBr, cm-1) &max: 3061, 2359, 2229, 1582, 1511, 1359, 1235, 1091,
1060. 1HNMR: (300 MHz, CDCl3) & 7.36 (m, 2H), 7.09 (s, 1H), 6.89 (m, 2H), 4.69 (s, 2H), 4.45
(s, 2H), 3.81 (s, 3H), 2.58 (s, 3H), 2.53 (s, 3H). 13CNMR (300 MHz, CDCl3) & 156.87, 154.03,
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145.80, 139.65, 124.62 (2C), 123.83, 118.29, 110.20, 108.44 (2C), 105.45, 85.84, 77.63, 65.97,
51.61, 49.88, 19.39, 14.91.

2-(3-((4-Methoxybenzyloxy)propyl)-4,6-dimethylnicotinonitrile (12b):

Hydrogenation was conducted on a mixture of 2-(3-((4-methoxybenzyloxy)prop-1-ynyl)-4,6dimethylnicotinonitrile (350 mg, 1.14 mmol) and Pd/C (35 mg, 10% by weight) in MeOH (25
mL) under 46 psi H2 for 18 hours. The mixture was filtered through celite to remove Pd/C and
concentrated to remove MeOH to give 2-(3-((4-methoxybenzyloxy)propyl)-4,6dimethylnicotinonitrile (310 mg, 87% yield) as a white powder. M.p.: 34-35!. IR (KBr, cm-1)
&max: 2916, 2844, 2216, 1596, 1514, 1245, 1111, 1039. 1HNMR: (300 MHz, CDCl3) & 7.27 (m,
2H), 6.94 (s, 1H), 6.87 (m, 2H), 4.45 (s, 2H), 3.80 (s, 3H), 3.55 (t, J=6.3 Hz, 2H), 3.06 (m, 2H),
2.53 (s, 3H), 2.47 (s, 3H), 2.09 (m, 2H) 13CNMR (300 MHz, CDCl3) & 164.24, 160.93, 158.64,
150.77, 130.21, 128.80 (2C), 121.403, 116.09, 113.28 (2C), 106.35, 72.04, 68.87, 54.865, 33.58,
28.77, 24.422, 19.92.

2-(3-((4-Methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3-carbaldehyde (13b):

Under N2 protection, 2-(3-((4-methoxybenzyloxy)propyl)-4,6-dimethylnicotinonitrile (250 mg,
0.80 mmol) was dissolved in anhydrous toluene (6 mL) then cooled to 0˚C. After cooling,
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DIBAL-H (0.96 mL of 1.0 M solution of in toluene, 0.96 mmol) was added dropwise over 60
minutes and stirred at 0! for 2 hours. Then 1.0 M H2SO4 (3.0 mL) was added and the resulting
solution was allowed to warm to room temperature and stirred overnight. The organic layer was
separated; the aqueous layer was extracted with EtOAc (25 mL) three times. The combined
organic layers were washed with saturated aqueous NaHCO3, brine, and dried over Na2SO4,
filtered and concentrated. The crude product was purified by column chromatography on silica
gel with hexane:EtOAc (3:1 v/v) as eluent to give 2-(3-((4-methoxybenzyloxy)propyl)-4,6dimethylpyridine-3-carbaldehyde (181 mg, 71% yield) as a colorless oil. IR (KBr, cm-1) &max:
2924, 2852, 1688, 1588, 1247. 1HNMR: (300 MHz, CDCl3) & 10.56 (s, 1H), 7.25 (m, 2H), 6.90
(s, 1H), 6.87 (m, 2H), 4.42 (s, 3H), 3.80 (s, 3H), 3.50 (t, J=6.3Hz, 2H), 3.18 (m, 2H), 2.55 (s,
3H), 2.51 (s, 3H), 2.01 (m, 2H). 13CNMR (300 MHz, CDCl3) & 192.65, 164.62, 162.12, 159.34,
150.12, 130.80, 129.5 (2C), 126.12, 124.86, 113.97 (2C), 72.74, 69.38, 55.45, 34.89, 29.28,
24.924, 20.92.

2-(3-((4-Methoxybenzyloxy)propyl)-4,6-dimethyl-3-(Z)-dec-1-enyl)pyridine (15b) and 2-(3((4-Methoxybenzyloxy)propyl)-4,6-dimethyl-3-(E)-dec-1-enyl)pyridine:

Wittig: Under N2 protection, non-1-yl triphenylphosphonium bromide (844 mg, 1.8 mmol) in
anhydrous toluene (10 mL) and LHMDS (1.6 mL of a 1.0 M solution in THF, 1.6 mmol) were
dissolved producing a bright red color. The solution was cooled to -70! then 2-(3-((4-
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methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3-carbaldehyde (280 mg, 0.9 mmol) in
anhydrous toluene (5 mL) was added dropwise over 20 minutes diluting the dark red color of the
reaction mixture to yellow. The reaction was stirred at -70! for 15 minutes then warmed to
room temperature. After 2 hours at room temperature, the reaction was quenched with saturated
aqueous NH4Cl (15 mL) producing a colorless solution. The organic layer was separated, the
aqueous layer was extracted with CH2Cl2 (15 mL) three times. The combined organic layers were
washed with saturated aqueous NaHCO3, brine, dried over Na2SO4, filtered and concentrated.
The crude product was purified by column chromatography on silica gel with hexane:EtOAc (8:1
v/v) as eluent to give a mixture of 2-(3-((4-methoxybenzyloxy)propyl)-4,6-dimethyl-3-(Z)-dec-1enyl)pyridine and 2-(3-((4-methoxybenzyloxy)propyl)-4,6-dimethyl-3-(E)-dec-1-enyl)pyridine
(300 mg, 79% yield) as a colorless oil. 1HNMR indicated 1:1 E:Z ratio. Schlosser Modification
to the Wittig Reaction: Under N2 protection, non-1-yl triphenylphosphonium bromide (235 mg,
0.5 mmol) and LiBr (117 mg, 1.35 mmol) were suspended in a THF:toluene solution (10 mL,
2:3 v/v). PhLi (0.38 mL of a 1.8 M solution in diisopropyl ether, 0.675 mmol) was added
dropwise producing a bright red color. The resulting solution was cooled to -70!. 2-(3-((4Methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3-carbaldehyde (140 mg, 0.45 mmol) in
toluene (1 mL) was added dropwise to the solution resulting in a lighter solution. Batch 2: After
30 minutes at -70!, 4 mL of the reaction solution was removed by syringe in placed into a cold,
dry flask (flask 2) while the other approximately two thirds of the reaction continued to stir at
-70!. A solution of PhLi and LiBr (0.11 mL of a 1.8 M PhLi solution in diisopropyl ether, 0.20
mmol and 17 mg of LiBr, 0.20 mmol) in THF (1.0 mL) was added to flask 2, containing the
smaller portion of the reaction mixture. After 30 minutes stirring at -70!, the reaction mixture
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in flask 2 was warmed to -25! and 1 M ethereal HCl (0.65 mL, 1 M solution in diethyl ether,
0.65 mmol) was added turning the reaction mixture to a colorless solution. After a few minutes,
t-BuOK (78 mg, 0.70 mmol) was added to the reaction. The reaction was allowed to warm to
room temperature and stirred for two hours. Then water (7 mL) was added. The organic layer
was separated. The aqueous layer was extracted with EtOAc (20 mL) two times. The combined
organic layers were washed with saturated aqueous NaHCO3, brine, and dried over Na2SO4,
filtered and concentrated. The 100 mg crude product was purified by column chromatography on
silica gel with hexane:EtOAc (8:1 v/v) as eluent to give isomers 15a (18 mg, 30% yield) as a
colorless oil. 1HNMR indicated 1:2 E:Z ratio. Batch 1: The first reaction flask was allowed to
warm slowly to 0! then a solution of PhLi and LiBr (0.22 mL of a 1.8 M PhLi solution in
diisopropyl ether, 0.40 mmol and 38 mg of LiBr, 0.40 mmol) in THF (2.0 mL) was added,
containing the smaller portion of the reaction mixture. After 30 minutes stirring at 0!, 1 M
ethereal HCl (1.3 mL, 1 M solution in diethyl ether, 1.3 mmol) was added turning the reaction
mixture to a colorless solution. After a few minutes, t-BuOK (156 mg, 1.4 mmol) was added to
the reaction. The reaction was allowed to warm to room temperature and stirred for two hours.
Then water (14 mL) was added. The organic layer was separated. The aqueous layer was
extracted with EtOAc (40 mL) two times. The combined organic layers were washed with
saturated aqueous NaHCO3, brine, and dried over Na2SO4, filtered and concentrated. The 200 mg
crude product was purified by column chromatography on silica gel with hexane:EtOAc (8:1 v/
v) as eluent to give isomers 15a (30 mg, 25% yield) as a colorless oil. 1HNMR indicated 1:3 E:Z
ratio. Grignard Reaction: Pieces of Mg ribbon and a small amount of iodine were put in a 2
neck flask with a condenser and degassed and filled with N2 three times. Anhydrous THF (1 mL)
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was added. 1-bromononane (0.32 mL, 1.69 mmol) was added slowly, the reaction was heated
with a hot gun, then with an oil bath to maintain a slight reflux. An additional 0.1 mL 1bromononane was added and the reaction refluxed for two hours. After two hours the reaction
mixture looked clear and there was no visible Mg. It was cooled to -70! and 2-(3-((4Methoxybenzyloxy)propyl)-4,6-dimethylpyridine-3-carbaldehyde (40 mg, X mmol) in THF (0.3
mL) was added dropwise. The reaction mixture was stirred for an hour at -70!, one hour at 0!,
one hour at room temperature and overnight at reflux. TLC monitoring showed no product had
formed. In the morning, the reaction was quenched with 10 mL NH4Cl then the layers were
disposed. The starting material was not recovered. 2-(3-((4-Methoxybenzyloxy)propyl)-4,6dimethyl-3-(Z)-dec-1-enyl)pyridine (15b): 1HNMR (400MHz, CDCl3) & 7.25 (m, 2H), 6.86 (m,
2H), 6.82 (s, 1H), 6.24 (d, J= 11.1 Hz, 1H), 5.78 (d of t, J= 11.1 Hz, 7.3 Hz, 1H), 4.42 (s, 2H),
3.80 (s, 3H), 3.48 (t, J= 6.6 Hz, 2H), 2.75 (m, 2H), 2.46 (s, 3H), 2.14 (s, 3H), 1.93 (m, 2H), 1.77
(m, 2H), 1.21 (m, 12 H), 0.86 (m, 3H). 13CNMR (400MHz, CDCl3) & 159.06, 158.52, 155.43,
145.64, 134.89, 130.96, 129.10 (2C), 128.74, 124.81, 121.95, 113.71 (2C), 72.27, 70.01, 55.28,
32.58, 31.85, 29.71, 29.42, 29.38, 29.22, 28.97, 28.16, 24.08, 22.65, 19.87, 14.09. 2-(3-((4Methoxybenzyloxy)propyl)-4,6-dimethyl-3-(E)-dec-1-enyl)pyridine

1HNMR

(400MHz,

CDCl3) & 7.24 (m, 2H), 6.86 (m, 2H), 6.80 (s, 1H), 6.28 (d, J= 14.2 Hz, 1H), 5.65 (d of t, J= 14.2
Hz, 6.9 Hz, 1H), 4.42 (s, 2H), 3.80 (s, 3H), 3.49 (m, 2H), 2.84 (m, 2H), 2.44 (s, 3H), 2.22 (s,
3H), 1.98 (m, 2H), 1.77 (m, 2H), 1.45 (m, 2H), 1.21 (m, 10 H), 0.85 (m, 3H).
(400MHz, CDCl3)

13CNMR

& 159.06, 158.51, 154.94, 145.34, 137.15, 130.95, 130.01, 129.09 (2C),

125.07, 122.42, 113.71 (2C), 72.32, 69.97, 55.28, 33.41, 32.58, 31.91, 29.60, 29.48, 29.37,
29.33, 29.28, 24.03, 22.69, 20.47, 14.11.
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3-(4,6-Dimethyl-3-((Z)-dec-1-enyl)pyridin-2-yl)pronan-1-ol (16b) and 3-(4,6-dimethyl-3((E)-dec-1-enyl)pyridin-2-yl)pronan-1-ol:

Two equal batches of and isomeric mixture of 2-(3-((4-methoxybenzyloxy)propyl)-4,6dimethyl-3-(Z)-dec-1-enyl)pyridine and 2-(3-((4-methoxybenzyloxy)propyl)-4,6-dimethyl-3-(E)dec-1-enyl)pyridine (175 mg, 0.41mmol) were refluxed in EtOH (9 mL) and 1N HCl (4.5 mL)
for 3 hours. Each solution was concentrated to remove EtOH and extracted with CH2Cl2 (15 mL)
three times. The combined organic layers of both reactions were washed with brine, dried over
Na2SO4, filtered, and concentrated to give a crude oil. The combined crude product was purified
by column chromatography on silica gel with CH2Cl2/MeOH (50:1, v/v) as eluent to give a
mixture of 3-(4,6-dimethyl-3-((Z)-dec-1-enyl)pyridin-2-yl)pronan-1-ol and 3-(4,6-dimethyl-3((E)-dec-1-enyl)pyridin-2-yl)pronan-1-ol (210 mg, 84% yield) as a yellow oil. The isomers were
separated on prep arative TLC plates with Hexane/EtOAc (2:1, v/v) as eluent developed 4 times
to give as the top band 3-(4,6-dimethyl-3-((Z)-dec-1-enyl)pyridin-2-yl)pronan-1-ol (50 mg,
100% purity) and as the lower band 3-(4,6-dimethyl-3-((E)-dec-1-enyl)pyridin-2-yl)pronan-1-ol
(60 mg, 80% purity). 3-(4,6-Dimethyl-3-((Z)-dec-1-enyl)pyridin-2-yl)pronan-1-ol (16b):
1HNMR

(400MHz, CDCl3) & 6.85 (s, 1H), 6.22 (d, J=11.2 Hz, 1H), 5.83 (d of t, J=11.2, 7.5 Hz,

1H), 3.69 (m, 2H), 2.95 (m, 2H), 2.51 (s, 3H), 2.18 (s, 3H) 1.88 (m, 2H), 1.77 (m, 2H), 1.20 (m,
12 H), 0.86 (m, 3H).

13CNMR

(400MHz, CDCl3) & 157.79, 154.79, 146.56, 135.28, 129.07,

124.57, 122.19, 62.79, 33.35, 32.84, 30.28, 29.40, 29.33, 29.20, 28.95, 28.81, 23.48, 22.64,
19.97, 14.08. 3-(4,6-Dimethyl-3-((E)-dec-1-enyl)pyridin-2-yl)pronan-1-ol: 1HNMR (400MHz,
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CDCl3) & 6.83 (s, 1H), 6.26 (d, J=16.0 Hz, 1H), 5.65 (d of t, J=16.0, 6.9 Hz, 1H), 3.68 (m, 2H),
3.00 (m, 2H), 2.91 (m, 2H), 2.43 (s, 3H), 2.23 (s, 3H) 1.91 (m, 2H), 1.76 (m, 2H), 1.45 (m, 2H),
1.21 (m, 8H), 0.867(m, 3H).

13CNMR

(400MHz, CDCl3) & 157.76, 154.30, 146.22, 137.58,

130.43, 124.86, 122.58, 62.56, 33.39, 32.89, 30.68, 29.45, 29.32, 29.20, 28.95, 28.81, 23.48,
22.67, 20.48, 14.10.

D. Final products in series b
8-Dec-1-(Z)-enyl-5,7-dimethyl-2,3-dihydro-1H-indolizinium chloride (1b):

MsCl (37 mg, 0.33 mmol) in CH2Cl2 (1.0 mL) was added to an ice cold solution of 3-(4,6dimethyl-3-((Z)-dec-1-enyl)pyridin-2-yl)pronan-1-ol (50 mg, 0.165 mmol), TEA (50 mg, 0.50
mmol) in CH2Cl2 (3.0 mL). The reaction was warmed to room temperature over 60 minutes. The
mixture was diluted with CH2Cl2 (20 mL), washed with brine, dried over Na2SO4, filtered and
concentrated to give a crude product (60 mg). The crude product was separated by column
chromatography on silica gel with CH2Cl2/MeOH (50:3, v/v) as eluent to give 8-dec-1-(Z)enyl-5,7-dimethyl-2,3-dihydro-1H-indazolinium chloride (40 mg) as a colorless oil in 70 %
yield. 1HNMR: (400 MHz, CD3CN) & 7.55 (s, 1H), 6.24 (d, J=10.8 Hz, 1H), 6.03 (d of t, J=10.8
Hz, 7.6 Hz, 1H), 4.61 (m, 2H), 3.22 (m, 2H), 2.66 (s, 3H), 2.38 (m, 2H), 2.31 (s, 3H), 1.82 (m,
2H), 1.34 (m, 2H), 1.21 (m, 10 H), 0.87 (m, 3H). Z

13CNMR:

(400 MHz, CD3CN) & 156.50,
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156.04, 149.76, 138.56, 131.55, 127.03, 120.43, 56.53, 31.84, 31.46, 28.90, 28.81, 28.79, 28.67,
28.31, 22.24, 20.42, 19.34, 18.70, 13.25. MS m/z: 287.13.

8-dec-1-(E)-enyl-5,7-dimethyl-2,3-dihydro-1H-indolizinium chloride (17b) and isomer
(16b):
MsCl (45 mg, 0.4 mmol) in CH2Cl2 (1.0 mL) was added to an ice cold solution of 3-(4,6dimethyl-3-((E)-dec-1-enyl)pyridin-2-yl)pronan-1-ol (60 mg, 0.2 mmol), TEA (60 mg, 0.60
mmol) in CH2Cl2 (3 mL). The reaction was warmed to room temperature over 60 minutes. The
mixture was diluted with CH2Cl2 (20 mL), washed with brine, dried over Na2SO4, filtered and
concentrated to give a crude product (80 mg). The crude product was separated by column
chromatography on silica gel with CH2Cl2/MeOH (50:3, v/v) as eluent to give 8-dec-1-(E)enyl-5,7-dimethyl-2,3-dihydro-1H-indazolinium chloride
50 mg, 83% yield) as a colorless oil. 1HNMR: (400 MHz, CD3CN) & 7.52 (s, 1H), 6.37 (d,
J=16.4 Hz, 1H), 6.10 (d of t, J=16.4 Hz, 6.8 Hz, 1H), 4.63 (m, 2H), 3.42 (m, 2H), 2.65 (s, 3H),
2.47 (m, 3H), 2.38 (m, 2H), 2.28 (m, 2H), 1.52 (m, 2H), 1.28 (m, 10 H), 0.88 (m, 3H). 13CNMR:
(400 MHz, CD3CN) & 155.31, 155.00, 148.84, 141.19, 131.70, 127.28, 121.266, 56.25, 32.71,
32.20. 31.28, 28.76, 28.66, 28.49, 28.21, 22.05, 20.43, 19.53, 18.54, 13.06. MS m/z: 286.02.

8-Decyl-5,7-dimethyl-2,3-dihydro-1H-indolizinium (20b)
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Hydrogenation was conducted on a mixture of isomers (30 mg, xx mmol) and Pd/C (3 mg, 10%
by weight) in MeOH (2 mL) under 50 psi H2 for 12 hours. The mixture was filtered through
celite to remove Pd/C and concentrated to remove MeOH to give 20 mg (67% yield) 8-decyl-5,7dimethyl-2,3-dihydro-1H-indolizinium. 1HNMR (400MHz, CD3CN) & 7.43 (s, 1H), 4.54 (m,
2H), 3.39 (m, 2H), 2.69 (m, 2H), 2.60 (s, 3H), 2.48 (s, 3H), 2.41 (m 2H), 1.49 (m, 2H), 1.40 (m,
2H) 1.29 (m, 12 H) 0.89 (m, 3H).

13CNMR

(400MHz, CD3CN) & 155.96,

154.51, 149.76,

134.98, 127.40, 56.12, 31.30, 30.76, 28.97, 28.91, 28.71, 28.66, 28.50, 27.55, 22.55, 22.07,
20.03, 18.41, 18.33, 13.06. MS m/z: 289.2.

E. Intermediates in synthesis of series c:
3-Morpholinobut-2-enenitrile (7):

A neat mixture of morpholine (435 mg, 5 mmol), triethyl orthoacetate (810 mg, 5 mmol), and
cyanoacetic acid (535 mg, 5 mmol) was refluxed for 4 hours. The solution was concentrated to
remove ethanol and the crude residue was diluted with CH2Cl2 (3 mL), washed with saturated
aqueous NaHCO3 (2 mL), dried over Na2SO4, filtered and concentrated to give 675 mg crude red
oil. The crude product was purified by column chromatography on silica gel with a hexane:ethyl
acetate solvent system (2:1 v/v) to give 3-morpholinobut-2-enenitrile (300 mg, 40% yield) as a
colorless solid. M.p.: 38-40!. IR (KBr, cm-1) &max: 2194, 1585, 1439, 1380, 1250, 1123, 1005.
1HNMR

(300MHz, CDCl3) & 3.98 (s, 1H), 3.72 (m, 4H), 3.16 (m, 4H), 2.16 (s, 3H). 13CNMR

(300MHz, CDCl3) & 161.62, 121.20, 65.63 (2C), 65.27, 46.02 (2C), 17.97.
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6-Hydroxy-2,4-dimethylnicotinonitrile (2c)

3-Morpholinobut-2-enenitrile ( 200 mg, 1.3 mmol) was refluxed in acetic acid (1 mL) for 7
hours. After cooling to room temperature, the reaction was concentrated to remove acetic acid.
The crude residue was purified by column chromatography on silica gel with CH2Cl2:MeOH
(30:1 v/v) as eluent to yield 6-hydroxy-2,4-dimethylnicotinonitrile (75 mg, 77% yield) as a white
powder. M.p.: decomposed at 247-250!. IR (KBr, cm-1) &max: 2916, 2205, 1648. 1HNMR
(300MHz, DMSO) & 12.2 (br, 1H), 6.16 (s, 1H), 2.38 (s, 3H), 2.20 (s, 3H). 13CNMR (300MHz,
DMSO) & 162.75, 155.87, 151.14, 117.31, 116.79, 91.59, 20.80, 19.18.

6-Bromo-2,4-dimethylnicotinonitrile (8c):

A solution of 6-hydroxy-2,4-dimethylnicotinonitrile (74 mg, 0.5 mmol), TBAB (193 mg,0.6
mmol) and P2O5 (177 mg, 1.25 mmol) was heated in toluene (25 mL) under N2 protection for 1.5
hours. Ice was added to the hot reaction mixture and the organic layer was separated. The
aqueous layer was extracted with EtOAc (25 mL) twice. The combined organic layers were
washed with saturated aqueous NaHCO3, dried over Na2SO4, filtered and concentrated to give 96
mg crude product. The crude product was purified by column chromatography on Al2O3 with
hexane:ethyl acetate (20:1 v/v) solvent system to give 6-bromo-2,4-dimethylnicotinonitrile (75
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mg, 71% yield) as a white solid. M.p.: 67-69!. IR (KBr, cm-1) &max: 3050, 2359, 2341, 2221,
1571. 1HNMR (300MHz, DMSO) & 7.72 (s, 1H), 2.64 (s, 3H), 2.46 (s, 3H). 13CNMR (300MHz,
DMSO): & 163.02, 154.97, 144.90, 127.12, 166.36, 109.82, 23.82, 20.33.

6-(3-((4-Methoxybenzyloxy)prop-1-ynyl)-2,4-dimethylnicotinonitrile (11c):

To a stirred suspension of 6-bromo-2,4-dimethylnicotinonitrile (40 mg, 0.18 mmol), CuI, (3 mg,
0.018 mmol), PdCl2(PPh3)2 (6 mg, 0.009 mmol), and triethylamine (0.75 mL) in diethyl ether
(2.5 mL) was added 1-methoxy-4-((prop-2-ynyloxy)methyl)benzene in diethyl ether (2.5 mL)
dropwise under N2 protection. The reaction was stirred under N2 protection for 2.5 hours. Then
water (5 mL) was added. The organic layer was separated, the water layer was extracted twice
with EtOAc (10 mL). The combined organic layers were washed with brine and dried over
Na2SO4, filtered and concentrated. The 50 mg of crude residue was purified by column
chromotagraphy on silica gel with a Hexane/EtOAc solvent system (20:3 v:v) to give 6-(3-((4methoxybenzyloxy)prop-1-ynyl)-2,4-dimethylnicotinonitrile (35 mg , 63% yield). M.p.:
106-107!. IR (KBr, cm-1) &max: 3051, 2999, 2906, 2215, 1606, 1575, 1249, 1179, 1029. 1HNMR
(300MHz, CDCl3) & 7.3 (m, 2H) 7.24 (s, 1H) 6.9 (m, 2H), 4.6 (s, 2H), 4.4 (s, 2H), 3.8 (s, 3H),
2.75 (s, 3H), 2.52 (s, 3H). 13C NMR (300MHz, CDCl3) & 162.24, 159.71, 151.87, 144.59, 130.04
(2C), 129.37, 125.56, 116.146, 114.100 (2C), 109.49, 89.23, 85.05, 72.00, 57.55, 55.52, 24.09,
20.55.
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6-(3-((4-Methoxybenzyloxy)propyl)-2,4-dimethylnicotinonitrile (12c)

Hydrogenation was conducted on a mixture of 6-(3-((4-methoxybenzyloxy)prop-1-ynyl)-2,4dimethylnicotinonitrile (230 mg, 0.33 mmol) and Pd/C (23 mg, 10% by weight) in MeOH (30
mL) under 50 psi H2 for 4.5 hours. The mixture was filtered through celite to remove Pd/C and
concentrated to remove MeOH to give

6-(3-((4-methoxybenzyloxy)propyl)-2,4-

dimethylnicotinonitrile (200 mg, 87% yield) as a colorless oil. IR (KBr, cm-1) &max: 3051, 2921,
2849, 1617, 1513, 1460, 1376, 1250. 1HNMR (300MHz, CDCl3) & 7.24 (m, 2H), 6.90 (s, 1H),
6.87 (m, 2H), 4.42 (s, 2H), 3.81 (s, 3H) 3.47 (t, J=6.3 Hz, 2H), 2.84 (m, 2H), 2.71 (s, 3H), 2.46
(s, 3H). 2.00 (m, 2H).

13C

NMR (300MHz, CDCl3) & 164.91, 161.49, 159.37, 151.42, 130.71,

129.49 (2C), 121.54, 116.86, 113.95 (2C), 107.43, 72.77, 69.18, 55.48, 35.35, 29.60, 24.03,
20.56.

6-(3-((4-Methoxybenzyloxy)propyl)-2,4-dimethylpyridine-3-carbaldehyde (13c):

Under N2 protection, 6-(3-((4-methoxybenzyloxy)propyl)-2,4-dimethylnicotinonitrile (180 mg,
0.58 mmol) was dissolved in anhydrous toluene (6 mL) then cooled to 0!. After cooling,
DIBAL-H (0.64 mL of 1.0 M solution of in toluene, 0.64 mmol) was added dropwise over 45
minutes and stirred at 0! for 1.5 hours. Then 1.0 M H2SO4 (4 mL) was added and the resulting
solution was allowed to warm to room temperature and stirred 4 hours. The organic layer was
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separated; the aqueous layer was extracted with EtOAc (15 mL) three times. The combined
organic layers were washed with saturated aqueous NaHCO3, brine, dried over Na2SO4, filtered
and concentrated to give 150 mg crude product. The crude product was purified by column
chromatography on silica gel with hexane:EtOAc (3:1 v/v) as eluent to give 6-(3-((4methoxybenzyloxy)propyl)-2,4-dimethylpyridine-3-carbaldehyde (135mg, 75% yield) as a
colorless oil. IR (KBr, cm-1) &max: 2927, 2844, 1690, 1586, 1240, 1101, 1045. 1HNMR (300MHz,
CDCl3) & 10.58 (s, 1H), 7.26 (m, 2H), 6.88 (s, 1H), 6.87 (m, 2H), 4.44 (s, 2H), 3.81 (s, 3H), 3.49
(t,J=6.3 Hz, 2H), 2.88 (m, 2H), 2.79 (s, 3H), 2.56 (s, 3H), 2.02 (m, 2H). 13C NMR (300MHz,
CDCl3) & 192.53, 165.49, 160.96, 159.36, 150.33, 130.77, 129.52 (2C), 126.37, 124.34, 113.96
(2C), 72.79, 69.35, 55.51, 35.27, 29.67, 23.40, 20.64.

2-(3-((4-Methoxybenzyloxy)propyl)-4,6-dimethyl-5-(Z)-dec-1-enyl)pyridine (15c)
and 2-(3-((4-methoxybenzyloxy)propyl)-4,6-dimethyl-5-(E)-dec-1-enyl)pyridine:

Wittig Reaction: Under N2 protection, non-1-yl triphenylphosphonium bromide (300 mg, 0.63
mmol) in toluene (3 mL) and LHMDS (0.57 mL of a 1.0 M solution of in THF, 0.57 mmol) were
dissolved producing a bright red color. The solution was cooled to -70˚C using a dry-ice/acetone
bath then 6-(3-((4-methoxybenzyloxy)propyl)-2,4-dimethylpyridine-3-carbaldehyde (100 mg,
0.32 mmol) in toluene (2 mL) was added dropwise over 20 minutes. The reaction was stirred at
-70! for 15 minutes then warmed to room temperature. After stirring for an hour at room
temperature, the reaction was quenched with saturated aqueous NH4Cl (10 mL) producing a
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colorless solution. The organic layer was separated, the aqueous layer was extracted with CH2Cl2
(15 mL) three times. The combined organic layers were washed with saturated aqueous
NaHCO3, brine, dried over Na2SO4, filtered and concentrated to give 300 mg crude product. The
crude product was purified by column chromatography on silica gel with hexane:EtOAc (10:1 v/
v) as eluent to give isomers 2-(3-((4-methoxybenzyloxy)propyl)-4,6-dimethyl-5-(Z)-dec-1enyl)pyridine and 2-(3-((4-methoxybenzyloxy)propyl)-4,6-dimethyl-5-(E)-dec-1-enyl)pyridine:
(90 mg, 67% yield) as a colorless oil. 1HNMR indicated 3:5 E:Z ratio. Schlosser Modification
to the Wittig reaction: Under N2 protection, to a solution of non-1-yl triphenylphosphonium
bromide (223 mg, 0.47 mmol) and LiBr (83 mg, 0.95 mmol) in an anhydrous toluene/THF
solution (8 mL total, 3:1 v/v) was added PhLi (0.26 mL of a 1.8 M solution in diisopropyl ether,
0.47 mmol) producing an orange solution. An additional equivalent of PhLi (0.26 mL of a 1.8 M
solution in diisopropyl ether, 0.47 mmol) was added, resulting in a dark red solution. The
resulting solution was cooled to -70!. 6-(3-((4-Methoxybenzyloxy)propyl)-2,4dimethylpyridine-3-carbaldehyde (135 mg, 0.43 mmol) was dissolved in toluene (1 mL) and
added dropwise to the solution resulting in an orange solution. After 1 hour, the reaction was
slowly warmed to 0! and starting material disappeared from TLC plate. Then a mixture of PhLi
and LiBr (0.47 mmol) in THF (6 mL) was added returning the color to dark orange. The reaction
was stirred at 0! for an hour, then 1 M ethereal HCl (1.75 mL, 1 M solution in diethyl ether,
1.75 mmol), followed by addition of t-BuOK (192 mg, 2.15 mmol) in Et2O (3 mL) was added to
the reaction. The reaction mixture was allowed to warm to room temperature and stirred
overnight. Then water (10 mL) was added. The organic layer was separated. The aqueous layer
was extracted with EtOAc (30 mL) three times. The combined organic layers were washed with
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saturated aqueous NaHCO3, brine, dried over Na2SO4, filtered and concentrated. The crude
product was purified by column chromatography on silica gel with hexane:EtOAc (8:1 v/v) as
eluent to give isomers 2-(3-((4-methoxybenzyloxy)propyl)-4,6-dimethyl-5-(Z)-dec-1enyl)pyridine and 2-(3-((4-methoxybenzyloxy)propyl)-4,6-dimethyl-5-(E)-dec-1-enyl)pyridine
(140 mg, 77% yield) as a colorless oil.

1HNMR

indicated 1:2 E:Z ratio. 2-(3-((4-

methoxybenzyloxy)propyl)-4,6-dimethyl-5-(Z)-dec-1-enyl)pyridine (15c): 1HNMR (400MHz,
CDCl3) & 7.28 (m, 2H), 6.87 (m, 2H), 6.80 (s, 1H), 6.22 (d, J= 11.2 Hz, 1H), 5.78 (d of t, J= 11.2
Hz, 7.3 Hz, 1H), 4.45 (s, 2H), 3.80 (s, 3H), 3.51 (m, 2H), 2.77 (m, 2H), 2.39 (s, 3H), 2.13 (s,
3H), 2.01 (m, 2H), 1.77 (m, 2H), 1.21 (m, 12 H), 0.85 (m, 3H). 13CNMR (400MHz, CDCl3) &
159.12, 158.70, 155.32, 145.55, 134.73, 130.82, 129.39, 129.23 (2C), 125.19, 121.25, 113.76
(2C), 72.50, 69.57, 55.28, 34.57, 31.84, 29.98, 29.71, 29.38, 29.22, 28.96, 28.74, 23.11, 22.64,
19.85, 14.09. 2-(3-((4-methoxybenzyloxy)propyl)-4,6-dimethyl-5-(E)-dec-1-enyl)pyridine:
1HNMR

(400MHz, CDCl3) & 7.28 (m, 2H), 6.87 (m, 2H), 6.80 (s, 1H), 6.24 (d, J= 16.1 Hz, 1H),

5.78 (d of t, J= 16.1 Hz, 6.8 Hz, 1H), 4.44 (s, 2H), 3.80 (s, 3H), 3.49 (m, 2H), 2.77 (m, 2H), 2.48
(s, 3H), 2.23 (s, 3H), 2.01 (m, 2H), 1.47 (m, 2H), 1.25 (m, 12 H), 0.85 (m, 3H). E
(400MHz, CDCl3)

13CNMR

& 159.11, 158.70, 155.31, 145.55, 133.12, 130.81 129.39, 129.23 (2C),

125.41, 121.87, 113.76 (2C), 72.50, 69.51, 55.28, 33.44, 31.89, 29.99, 29.71, 29.45, 29.31,
29.18, 28.96, 28.74 23.63, 20.39, 14.11.

114

3-(4,6-Dimethyl-5-((Z)-dec-1-enyl)pyridin-2-yl)pronan-1-ol (16c) and 3-(4,6-dimethyl-5((E)-dec-1-enyl)pyridin-2-yl)pronan-1-ol

A mixture of isomers 2-(3-((4-methoxybenzyloxy)propyl)-4,6-dimethyl-5-(Z)-dec-1enyl)pyridine and 2-(3-((4-methoxybenzyloxy)propyl)-4,6-dimethyl-5-(E)-dec-1enyl)pyridine(140mg, 0.33 mmol) was refluxed in EtOH (6 mL) and 1N HCl (3 mL) for 3.5
hours. After cooling, the solution was concentrated to remove EtOH. The aqueous layer was
extracted with CH2Cl2 (30 mL) three times. The combined organic layers were washed with
brine, dried over Na2SO4, filtered and concentrated to give 180 mg crude product. The crude
product was purified by column chromatography on silica gel with CH2Cl2:MeOH (25:1 v/v) as
eluent to give isomers 3-(4,6-dimethyl-5-((Z)-dec-1-enyl)pyridin-2-yl)pronan-1-ol and 3-(4,6dimethyl-5-((E)-dec-1-enyl)pyridin-2-yl)pronan-1-ol (76 mg, 76% yield) as a colorless oil. IR
(KBr, cm-1) &max: 3443, 2924, 2853, 1593, 1461, 1067. (isomeric mixture) (16c) Z

13CNMR

(300MHz, CDCl3) & 157.52, 154.39, 146.07, 134.67, 129.24, 124.23, 121.33, 62.46, 35.34,
33.01, 31.42, 30.64, 28.95, 28.85, 28.78, 28.51, 22.23, 19.49, 13.67 13CNMR (300MHz, CDCl3)
& 156.96, 154.30, 145.57, 137.10, 130.26, 124.51, 121.40, 62.46, 35.34, 33.01, 31.42, 30.64,
29.28, 28.85, 28.34, 22.78, 22.23, 20.02, 13.67
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F. Final products in series c:
6-Dec-1-(Z)-enyl-5,7-dimethyl-2,3-dihydro-1H-indolizinium chloride (1c) and 6-dec-1-(E)enyl-5,7-dimethyl-2,3-dihydro-1H-indolizinium chloride (17c):

To a mixture of 3-(4,6-dimethyl-5-((Z)-dec-1-enyl)pyridin-2-yl)pronan-1-ol and 3-(4,6dimethyl-5-((E)-dec-1-enyl)pyridin-2-yl)pronan-1-ol (75 mg, 0.25 mmol) and triethyl amine (75
mg, 0.75 mmol) in CH2Cl2 (4 mL) at 0! was added MsCl (57 mg, 0.50 mmol) in CH2Cl2 (2.0
mL). The mixture was allowed to warm to room temperature over 1 hour, diluted with CH2Cl2
(20 mL), washed with brine, dried over Na2SO4, filtered and concentrated to give the crude
product (150 mg). The crude product was purified by column chromatography on silica gel with
CH2Cl2:MeOH (15:1 v/v) as eluent to give isomers 68-dec-1-(Z)-enyl-5,7-dimethyl-2,3dihydro-1H-indolizinium chloride and 6-dec-1-(E)-enyl-5,7-dimethyl-2,3-dihydro-1Hindolizinium chloride (60 mg, 75% yield) as a yellow oil. Separation of isomers was attempted
by both HPLC and prep TLC without success. 6-Dec-1-(Z)-enyl-5,7-dimethyl-2,3-dihydro-1Hindolizinium chloride/trifluroacetate (1c): 1HNMR (400MHz, CD3CN) & 7.61 (s, 1H), 6.26 (d,
J=11.3, 1H), 6.07 (d of t, J=11.3, 7.4 1H), 4.62 (m, 2H), 3.43 (m, 2H), 2.55 (s 3H), 2.41 (m, 2H),
2.39 (s, 3H), 1.78 (m, 2H), 1.22 (m, 12H) 0.89 (m, 3H). 13CNMR (400MHz, CD3CN) & 156.29,
155.64, 141.45, 138.22, 134.47, 121.72, 121.24, 56.82, 31.56, 31.27, 28.71, 28.62, 28.59, 28.22,
27.94, 22.01, 20.25, 17.04, 13.04. MS m/z: 286.21. 6-Dec-1-(E)-enyl-5,7-dimethyl-2,3dihydro-1H-indolizinium chloride /trifluroacetate (17c): 1HNMR (400MHz, CD3CN) & 7.58
(s, 1H), 6.32 (d, J=16.3, 1H), 5.87 (d of t, J=16.3, 6.9 1H) 4.62 (m, 2H), 3.43 (m, 2H), 2.63 (s,
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3H), 2.45 (s, 3H), 2.41 (m, 2H) 2.3 (m, 2H), 1.51 (m, 2H), 1.22 (m, 10H) 0.89 (m, 3H). 13CNMR
(400MHz, CD3CN) & 155.76, 155.02, 149.28, 138.22, 135.66, 121.92, 121.76, 56.94, 31.54,
31.27, 28.76, 28.66, 28.55, 28.14, 22.05, 20.56, 20.22, 17.37, 13.06. MS m/z: 286.21.

6-Decyl-5,7-dimethyl-2,3-dihydro-1H-indolizinium trifluroacetate (20c):

Hydrogenation was conducted on a mixture of isomers (15 mg, xx mmol) and Pd/C (2 mg, 10%
by weight) in MeOH (1.5 mL) under 50 psi H2 for 6 hours. The mixture was filtered through
celite to remove Pd/C and concentrated to remove MeOH to give 6-decyl-5,7-dimethyl-2,3dihydro-1H-indolizinium trifluroacetate. 1HNMR (400MHz, CD3CN) & 7.53 (s, 1H), 4.58 (m,
2H), 3.37 (m, 2H), 2.74 (m, 2H), 2.62 (s, 3H), 2.51 (s, 3H), 2.38 (m 2H), 1.44 (m, 4 H), 1.28 (m,
12 H) 0.89 (m, 3H).

13CNMR

(400MHz, CD3CN) & 155.91, 154.51, 149.76, 137.76, 122.33,

56.94, 48.47, 38.51, 31.44, 31.31, 28.96, 28.72, 28.67, 28.12, 27.94, 22.08, 20.19, 19.72, 16.10,
13.07. MS m/z: 289.04.

2. Biological screening of CCR5 antagonists
A. Cell Culture Method
All cell lines, PC-3, DU-145 and M12, were incubated at 37 ºC in the presence of 5% CO2.
RPMI 1640 serum free media (GIBCO Invitrogen) containing 1 % L-glutamine, 0.1% ITS
(insulin, 5µg/ml; transferrin, 5µg/ml; and selenium, 5 µg/ml; Collaborative Research, Bedford)
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and 0.1% gentamicin was used to cultivate all cells. M12 cells were first incubated in media with
5% fetal bovine serum (FBS); after 24 hours serum free media was added with 0.01% epidermal
growth factor (EGF). DU-145 and PC-3 cell lines were incubated in media containing 10% FBS
at all times.

B. Anti-proliferation Assay Protocol
Prostate cancer tumor cells (PC-3, M12, and DU-145) were plated into 96 well plates (BD
Falcon, VWR) at a concentration of 1000 cells per well. Each cell line was plated in its
respective serum containing media for a total concentration of 100 µL per well. After 24 hours,
various concentrations of drugs in a 50 µL water solution were added to the cells. Control cells
were given 50 µL of PBS. Seventy-two hours after incubation with drug, the serum containing
media was replaced with 100 µL of serum free media, followed by addition of 10 µL of
proliferative reagent WST-1 (Roche) to the wells. After 3 hours of incubation with WST-1, the
absorbance of each well was measured by a EL 312e Microplate Bio-kinetics Reader (BIO-TEK
Instruments). Percent inhibition of proliferation was calculated using a spreadsheet (Apple
Numbers 2009). The average absorbance of the cells with drug is subtracted from the average
absorbance of the cells without drug. This value is divided by the difference between the average
absorbance of the cells and the average absorbance of the media giving a decimal. Multiplying
this value by 100 yields the percent inhibition. The formula is as follows:
percent inhibition = [ (Acells – Adrug) / (Acells – Amedia) ] x 100
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Where Acells is the average absorbance of cells incubated without drug, Adrug is the average
absorbance of cells incubated with drug and Amedia is the average absorbance of the serum free
media.

3. Molecular Dynamics Simulations and Docking of Anibamine and Analogs
Previously two homology models of CCR5 were developed in our lab. The crystal
structures of bovine rhodopsin and !2 adrenergic receptor were used to construct the homology
models. The two homology models were accessed with anibamine bound. Parallel operations
were performed on both receptor models. To facilitate more flexibility in ligand docking of
anibamine analogs, a molecular dynamics simulation was performed to enlarge the binding
pocket with anibamine bound. An aggregate was defined as all monomers greater than 10 Å
away from the ligand and a distance constraint of 3 Å from the ligand nitrogen atom to O4276 on
Glu283 in the receptor model was imposed. Dynamics simulations were performed for 100,000
fs, taking a snapshot every 25 fs, with Gasteiger-Hückel charges and a dielectric constant of 4.0.
An average of the last 2000 fs was then minimized for 100,000 iterations with Gasteiger-Hückel and
a dielectric constant of 4.0. At this point the ligand was removed and Procheck was performed on
each receptor model. Amino acid residues with unfavorable sidechain angles were checked for
proximity to the binding pocket. All were located away from the proposed ligand binding site.

To build the molecular library, each compound was built in Sybyl 8.1, minimized for
100,000 iterations with Gasteiger-Hückel and a dielectric constant of 4.0 and saved. The core

template that was used for GOLD docking was constructed from the anibamine ligand extracted
from the minimized protein models. Both aliphatic sidechains of the extracted ligand were

119

removed and replaced with hydrogens. The structure was saved as a template for GOLD
docking.
Automated docking was performed on GOLD 3.1 Docking was performed using two
constraints. The first was a distance constraint between the nitrogen on the ligand to O4276 on
the receptor model of 2 to 4 Å. The second constraint was a similarity constraint by shape to the
core template created from anibamine. The number of operation was increased to 300,000 to
accommodate the flexible ligand sidechains. The active site was defined as a 10 Å radius from
O2476. All other parameters were left in their default settings. The top ranked configurations
were visualized in Sybyl.
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